A proposal on cancer data quality checks: one common procedure for European cancer registries (version 1.1) by MARTOS JIMENEZ MARIA DEL CARMEN et al.
EUR 29089 EN
J R C T E C H N I C A L R E P O R T S 
A proposal on cancer data quality checks: 
one common procedure 
for European cancer registries 
Carmen Martos, 
Emanuele Crocetti (Coordinator), 
Otto Visser, Brian Rous, 
Francesco Giusti and the 
Cancer Data Quality Checks Working Group 
2018 Version 1.1 • July 2018 
This publication is a Technical report by the Joint Research Centre (JRC), the European Commission’s science and knowledge 
service. It aims to provide evidence-based scientific support to the European policymaking process. The scientific output 
expressed does not imply a policy position of the European Commission. Neither the European Commission nor any person 
acting on behalf of the Commission is responsible for the use that might be made of this publication. 
Contact information 
Carmen Martos 
Address: Joint Research Centre, Directorate F – Health, Consumers and Reference Materials, Health in Society Unit, Via Enrico 
Fermi 2749, TP 127, 21027 Ispra (VA), Italy    
E-mail: carmen.martos@ec.europa.eu 
Tel.: +39 0332 78 9074 
JRC Science Hub 
https://ec.europa.eu/jrc 
JRC105078 
EUR 29089 EN 
Print ISBN 978-92-79-77890-2 ISSN 1018-5593 doi:10.2760/50693 
PDF ISBN 978-92-79-77889-6 ISSN 1831-9424 doi:10.2760/429053 
Luxembourg: Publications Office of the European Union, 2018 
© European Union, 2018 
Reuse is authorised provided the source is acknowledged. The reuse policy of European Commission documents is regulated 
by Decision 2011/833/EU (OJ L 330, 14.12.2011, p. 39). 
For any use or reproduction of photos or other material that is not under the EU copyright, permission must be sought directly 
from the copyright holders. 
How to cite this report: Carmen Martos, Emanuele Crocetti (Coordinator), Otto Visser, Brian Rous, Francesco Giusti and the 
Cancer Data Quality Checks Working Group, A proposal on cancer data quality checks: one common procedure for European 
cancer registries – version 1.1, EUR 29089 EN, Publications Office of the European Union, Luxembourg, 2018, 
ISBN 978-92-79-77890-2, doi:10.2760/50693, JRC105078. 
All images © European Union 2018 
Printed in Italy 
           EUR 29089 EN 
 
 
 
  
 
 
 
 
 
 
A proposal on cancer data quality checks: 
one common procedure 
for European cancer registries 
Carmen Martos, 
Emanuele Crocetti (Coordinator), 
Otto Visser, Brian Rous, 
Francesco Giusti and the 
Cancer Data Quality Checks Working Group 
2018 Version 1.1 • July 2018 
 
 
 
  
 
 
 
  
 
Table of Contents    |   3 
 
 
 
Table of Contents 
Working group on cancer data quality checks 4 
Contributors 5 
1. Introduction 7 
2. Case definition and variable format quality checks 9 
2.1. Case definition 9 
2.2. Variables and their format quality checks 9 
3. List of quality checks: internal consistency 15 
3.1. Consistency within variables 15 
3.2. Consistency between variables 26 
3.2.1. Coherence of dates 26 
3.2.2. Consistency between tumour data and demographic information 26 
Consistency between age/topography/morphology 26 
Consistency between sex/topography 28 
Consistency between sex/morphology 29 
3.2.3. Consistency between tumour variables 30 
Consistency between basis of diagnosis/morphology/behaviour 30 
Consistency between morphology/grade 31 
Consistency between topography/laterality 33 
Consistency between topography/morphology 33 
3.3. Specific additional checks for survival analysis 40 
3.4. Other additional checks on the extent of the disease 40 
4. Quality Checklist for Multiple Primary Malignant Tumours 42 
5. References 47 
Appendix I: The Anatomical Therapeutic Chemical code, generic name of the drug and trade name 48 
Appendix II: TNM 6 edition stage grouping and corresponding T, N, M values 54 
Appendix III: TNM 7 edition stage grouping and corresponding T, N, M values 73 
4   |   A proposal on cancer data quality checks: one common procedure for European cancer registries 
 
 
Working group on cancer data quality checks 
 
Claudia ALLEMANI CONCORD programme, London School of Hygiene Tropical Medicine, UK 
Manola BETTIO Joint Research Centre, European Commission 
Andrea BORDONI  ENCR-IACR Steering Committee  
Riccardo CAPOCACCIA EUROCARE project 
Helena CARREIRA CONCORD programme, London School of Hygiene Tropical Medicine, UK 
Emanuele CROCETTI (coordinator) ENCR-GRELL Steering Committee 
Roberta DE ANGELIS EUROCARE project 
Tadeusz DYBA Joint Research Centre, European Commission 
Nadia DIMITROVA ENCR Steering Committee 
Gerda ENGHOLM Danish Cancer Society 
Gemma GATTA RARECARE project 
Anna GAVIN ENCR Steering Committee 
Francesco GIUSTI Joint Research Centre, European Commission 
Alexander KATALINIC ENCR Steering Committee 
Carmen MARTOS Joint Research Centre, European Commission 
Pamela MINICOZZI EUROCARE project 
Giorgia RANDI Joint Research Centre, European Commission 
Ivan RASHID Italian Association of Cancer Registries 
Stefano ROSSO ENCR Steering Committee 
Brian ROUS National Cancer Registration Service, England, UK 
Milena SANT EUROCARE project 
Eva STELIAROVA-FOUCHER International Agency for Research on Cancer 
Hans STORM ENCR-ANCR Steering Committee 
Otto VISSER Integraal Kankercentrum Nederland 
Lydia VOTI Joint Research Centre, European Commission 
Helmut WALERIUS Directorate-General for Health and Consumer Protection, European Commission 
Working group on cancer data quality checks  |  Contributors    |   5 
 
 
Contributors 
 
Daniela ALESSI Childhood Cancer Registry of Piedmont 
Eva ARDANAZ Navarra Cancer Registry 
Mariangela AUTELITANO Cancer Registry of Milan 
Shiva AYOUBI Swedish Cancer Registry 
Simone BOECKMANN Cancer Registry of Lower Saxony 
Bertrand CAMEY Registre Fribourgeois des Tumeurs 
Léonie CASAGRANDA Association of the Childhood Cancer Registry of the Rhône-Alpes Region 
(ARCERRA) 
Helen CURRY West Midlands Regional Children’s Tumour Registry 
Silvia DEHLER Cancer Registry Zurich and Zug 
Nick DESSYPRIS Nationwide Registry for Childhood Haematological Malignancies– Brain 
Tumour (NaReCHeM– BT) 
Chakameh SAFAEI DIBA National Cancer Registry of Slovakia 
Silvia ESS St. Gallen-Appenzell & Grisons-Glarus 
Anna Clara FANETTI Registro Tumori della provincia di Sondrio– Sondrio Cancer Registry 
Gonçalo FORJAZ Azores Cancer Registry 
Zivana GAVRIC Cancer Registry Republika Srpska 
Adriano GIACOMIN Piedmont Cancer Registry, Province of Biella 
Stanisław GÓŹDŻ and Paweł MACEK Holycross Cancer Center 
Pascale GROSCLAUDE  Registries of FRANCIM Network 
Gaël HAMMER Registre Morphologique des Tumeurs au Grand-Duché de Luxembourg 
Christine HEAD National Cancer Registration Service for England 
Miriam HOLZMANN Cancer Registry of Schleswig-Holstein, Germany 
Kris HENAU and Liesbet VAN EYCKEN Belgian Cancer Registry 
Zsuzsanna JAKAB Hungarian Childhood Cancer Registry 
Rosario JIMÉNEZ, Ana I. MARCOS and JOSÉ MARÍA DíAZ Cancer Registry of Cuenca, 
Counselling of Health and Social Affairs, Castilla-La Mancha, Spain 
Margit MÄGI, TIIU AARELEID, Kaire INNOS and Mati RAHU Estonian Cancer Registry 
6   |   A proposal on cancer data quality checks: one common procedure for European cancer registries 
 
 
Rafael MARCOS-GRAGERA Girona Cancer Registry 
Luigino DAL MASO Friuli Venezia Giulia Cancer Registry 
Martin MEYER Population Based Cancer Registry Bavaria, Germany  
Ana MIRANDA Lisbon Cancer Institute– South Regional Cancer Registry 
Silvia PATRIARCA Piedmont Cancer Registry 
Josefina PERUCHA GONZÁLEZ La Rioja Cancer Registry 
Meike RESSING Cancer Registry Rhineland-Palatinate 
Anne SCHMIDT Cancer Registry Thurgau 
Giedre SMAILYTE Lithuanian Cancer Registry 
Giovanna TAGLIABUE Lombardy Cancer Registry, Varese Province 
Ana TORRELLA RAMOS Castellón Cancer Registry (Comunidad Valenciana), Spain 
SIGRÚN STEFÁNSDóTTIR Icelandic Cancer Registry 
Zdravka VALERIANOVA and Minka YORDANOVA Bulgarian National Cancer Registry 
Maja PRIMIC ŽAKELJ  Cancer Registry of Republic of Slovenia  
Miroslav ZVOLSKÝ Czech National Cancer Registry 
1.  Introduction   |   7 
 
 
 
   
 
The aim of population-based cancer regis- 
tries (CRs) is: a) to obtain information from 
all new cases in a well-defined geographic 
area to assess the magnitude of the cancer 
burden and its evolution, and b) to provide 
a basis for research on cancer causes and 
outcome (incidence, prevalence and sur- 
vival). Therefore, CRs contribute to mon- 
itoring the impact and effectiveness of 
policy implementation through monitoring 
outcomes such as incidence, prevalence or 
survival. The reliability and utility of the in- 
formation provided by CRs depends on the 
quality of the data collected. 
 
Three aspects are usually regarded when eval- 
uating the quality of the data in CRs: com- 
parability, completeness and validity. An 
additional quality indicator– the timeliness 
of registry procedures– is also considered. 
 
A variety of methods and tools have been 
used to check the data validity of CRs. 
Therefore, the European Network of Can- 
cer Registries (ENCR) in cooperation with 
the Joint Research Centre (JRC) has been 
working to establish a comprehensive and 
standardised list of data quality checks to be 
adopted by European CRs and European 
projects that would address the current frag- 
mented and sometimes conflicting situation 
regarding validation of data collected for 
different purposes. 
The adoption of a common list of variables, 
formats and standard data quality checks 
will improve the harmonisation of Euro- 
pean cancer data and the adherence to 
standardised data quality procedures will 
give CRs the opportunity to participate eas- 
ily in different international projects. 
 
Three workshops on data quality checks took 
place in JRC-Ispra, on 2 July and 15 October 
2013 and 4 June 2014 (http://www.encr.eu/). 
The outcome of the first two meetings was 
the creation of a comprehensive list of the 
existing data quality checks currently in place 
for various European projects, collected and 
summarised by the JRC. At the conclusion 
of the second workshop, agreements were 
reached for drafting a preliminary list of 
mandatory and basic variables and their 
formats. 
 
Furthermore, and in view of the third work- 
shop, the Working Group drafted a docu- 
ment ‘A proposal on cancer data quality 
checks: one common procedure for Euro- 
pean cancer registries’ taking into account 
the case definition, the list of variables and 
their format agreed upon during the second 
workshop, as well as the existing edits and 
the expertise of cancer registry experts. This 
report was disseminated among the Euro- 
pean CRs for consultation. 
. Introduction
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The report was the object of discussion and 
final revision at the third workshop, and 
final agreements were reached concerning 
case definition, variables and their format 
and data quality control list. 
 
This document is the result of a collabora- 
tive project between the ENCR, the JRC, the 
Working Group on Cancer Data Quality Checks 
and European cancer registries. The final 
outcome of the project was an ENCR- 
endorsed recommendations document, to be 
issued and presented at the 2014 ENCR 
Scientific Meeting and General Assembly, 12-
14 November 2014, at JRC-Ispra. 
 
This report focuses on case definitions and variable 
format quality checks and internal consistency within 
and between collected variables. The proposed 
quality checklist allows the identification of: 
impossible codes or code combinations, unlikely 
codes or code combinations and possible but 
very rare code or code combinations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Finally, the list of drugs used for chemother- 
apy, hormonal therapy, targeted therapy, 
immunotherapy and other therapies used in 
cancer treatment was revised and included 
in the Appendices: the list of drugs con- 
tains the Anatomical Therapeutic Chemical 
(ATC) code as well as the generic and trade 
names. 
 
With respect to the first version (1.0), in this 
updated version (1.1) of the report, the quality 
checklist of warnings for multiple primary 
malignant tumours (MPMT) according to the 
current International Rules for Primary Cancers 
published in 2004 have been added (Chapter 4). 
Moreover, Table 6 (Valid combinations for 
behaviour and topography/morphology) in the 
previous version of the report (1.0) has been 
discarded.  
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Case definition and variable format 
. quality checks 
 
The cancer data quality check list included 
in this report is based on the following case 
definition for CRs and European projects. 
 
2.1. Case definition 
 
• All primary malignant tumours (behav- 
iour = 3), including basal cell and squa- 
mous cell carcinomas of skin. 
• Benign tumours of the central nervous 
system (CNS). 
• Uncertain behaviour tumours of CNS 
and urinary bladder. 
• In situ tumours: breast, cervix, colon, rec- 
tum, urinary bladder and melanoma of 
the skin. 
 
 
Table 1. Quality checks for the variables and their formats. 
An extent of this case definition could be 
considered according to the European CRs 
needs in the future. 
 
2.2. Variables and their format 
quality checks 
 
During the second workshop on quality 
checks agreements were reached for the 
mandatory and basic variable list and their 
format. A revision of the list of variables and 
formats was made during the third work- 
shop. Table 1 shows the list of the variables: 
description, format, mandatory or non- 
mandatory status, missing/unknown values 
and the allowed values on which quality 
checks are based. 
 
Variable description Format Mandatory Missing/ un- 
known values 
Allowed values 
(Check flag) 
The ENCR-JRC QC list 
F1 Yes Not allowed Allowed values: 0, 1 
0 → Not checked 
1 → Checked 
Patient identification number A20 Yes (accord- 
ing to registry 
coding) 
Not allowed Not allowed to have duplicate 
combination of the two variables: 
Patient identification number 
+Tumour sequence number in 
the same dataset 
Tumour sequence number F2 Yes (accord-
ing to registry 
coding) 
Not allowed 
Day of birth A2 
DD 
Y 99 Range of allowed values: 
from 01 to 31 and 99 
Month of birth A2 
MM 
Y 99 Range of allowed values: 
from 01 to 12 and 99 
Warning for value = 99 
Year of birth F4 
YYYY 
Y 9999 Range of allowed values: 
>1842 and ≤ the current year 
Warning for value = 9999 
F: Numeric variable A: Alphanumeric variable Y= yes N= no 
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Table 1. (cont.) 
 
Variable description Format Mandatory Missing/ un- 
known values 
Allowed values 
Sex F1 Y 9 Allowed values: 1, 2, 3, 9 
1 → Male 
2 → Female 
3 → Other 
9 → Unknown 
Warning for value = 9 
Day: date of incidence A2 
DD 
Y 99 Range of allowed values: 
from 01 to 31 and 99 
Month: date of incidence A2 
MM 
Y 99 Range of allowed values: 
from 01 to 12 and 99 
Warning for value = 99 
Year: date of incidence 
ENCR recommendation 
for incidence date 
http://www.encr.eu/sites/default
/files/pdf/incideng.pdf 
F4 
YYYY 
Y Not allowed Range of allowed values: 
> 1941 and ≤ the current year 
Day of case registration A2 
DD 
N 99 Range of allowed values: 
from 01 to 31 and 99 
Month of case registration A2 
MM 
N 99 Range of allowed values: 
from 01 to 12 and 99 
Year of case registration F4 
YYYY 
N 9999 Range of allowed values: 
> 1941 and ≤ the current year 
Age at diagnosis in years F3 Y* 999 Range of allowed values: 
≥ 0 and < 121 
Warning for value = 999 if com-
pleted dates are not available 
Basis of diagnosis (BoD) 
ENCR recommendations 
http://www.encr.eu/sites/default
/files/pdf/basisd.pdf 
F1 Y 9 Allowed values: 0, 1, 2, 4, 5, 6, 7, 9 
0 → Death certificate only (DCO) 
1 → Clinical 
2 → Clinical investigation 
4 → Specific tumour markers 
5 → Cytology 
6 → Histology of a metastasis 
7 → Histology of a primary tumour 
9 → Unknown 
Warning for value = 9 
ICD-O-3 topography 
(topography of the metastasis is 
not admitted) 
A4 Y Not allowed Valid code in ICD-O-3. 
Warning for undefined  topography 
when BoD is 5 or 7 
C809; C76 (C760, C761, C762, 
C763, C764, C765, C767 
and C768); C14 (C140, C148); 
C26 (C260, C268, C269); C39 
(C390, C398, C399); C559; 
C579; C639; C689; C729; C759 
F: Numeric variable A: Alphanumeric variable Y= yes N= no 
* If complete date of birth and/or date of incidence are missing or unknown. 
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Table 1. (cont.) 
 
Variable description Format Mandatory Missing/ un- 
known values 
Allowed values 
ICD-O-3 morphology F4 Y Not allowed Valid code 
in ICD-O-3 
and updated 
in 2011 
Valid code in ICD-O-3 
and updated in 2011 
Warning for unde- 
fined morphology 
taking into account 
BoD 
(See Figure 2, p. 30) 
ICD-O-3 behaviour F1 Y Not allowed Accepted 
value: 
0-3 
Incidental finding of cancer 
at the autopsy 
F1 Y 9 Allowed values: 0, 1, 9 
0 → No 
1 → Yes 
9 → Unknown 
Warning for value = 9 
ICD-O-3 grade F1 Y 9 Allowed values: 1-9 
1 → Well differentiated, 
2 → Moderately differentiated 
3 → Poorly differentiated 
4 → Undifferentiated, anaplastic 
5 → T-cell; T-precursor 
6 → B-Cell; Pre-B; B-precursor 
7 → Null cell; Non T-non B 
8 → NK cell (natural killer cell) 
9 → Unknown 
Laterality of paired organs F1 N 9 Allowed values: 0-4, 9 
0 → Not applicable 
1 → Right 
2 → Left 
3 → Unilateral NOS 
4 → Bilateral 
9 → Unknown 
Vital status at last contact F1 Y 9 Allowed values: 1, 2, 9 
1 → Alive 
2 → Dead                                
9 → Unknown 
Warning for value = 9 
Day of the last known vital status A2 
DD 
Y 99 Range of allowed values: 
from 01 to 31 and 99 
Month of the last known vital 
status 
A2 
MM 
Y 99 Range of allowed values: 
from 01 to 12 and 99 
Warning for value = 99 
Year of the last known vital status F4 
YYYY 
Y 9999 Range of allowed values: 
> 1941 and ≤ the current year 
Warning for value = 9999 
Age at the last known vital status 
in years 
F3 Y** 999 Range of allowed values: 
≥ 0 and < 121 
Warning for value = 999 
F: Numeric variable A: Alphanumeric variable Y= yes N= no 
** If complete date of birth, data of incidence and/or date of end of follow-up are missing or unknown. 
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Table 1. (cont.) 
 
Variable description Format Mandatory Missing/ un- 
known values 
Allowed values 
Duration of survival in days F5 Y*** 99999 ≥ 0 
Warning for value = 99999 
Official underlying cause of death 
(ICD) 
A5 N 99999 Valid code in ICD 
according to ICD edition 
ICD edition used for coding cause 
of death 
F2 N 99 Range of allowed values: 
≥ 7 and ≤ 10 
It has to be periodically updated 
TNM stage, 
pathological primary site (pT) 
A6 N 999999 Prefix modifiers will be considered: 
y: stage assessed after neo- 
adjuvant therapy; 
a: stage determined at autopsy 
(See Table 2) 
TNM stage, 
pathological lymph nodes (pN) 
A4 N 9999 (See Table 2) 
TNM stage, 
pathological metastases (pM) 
A4 N 9999 (See Table 2) 
TNM stage, 
clinical primary site (cT) 
A5 N 99999 (See Table 2) 
TNM stage, 
clinical lymph nodes (cN) 
A3 N 999 (See Table 2) 
TNM stage, 
clinical metastases (cM) 
A3 N 999 (See Table 2) 
TNM stage grouping A4 N 9999 Based on pathological TNM if it 
is available or clinical TNM when 
pathological TNM is not available 
(See Table 2) 
TNM edition F2 N 99 Allowed values: 6, 7, 99 
It has to be periodically updated 
Condensed TNM, T 
ENCR recommendations 
http://www.encr.eu/sites/default/
files/pdf/extentofdisease.pdf 
A2 N 99 Allowed values: TL, TA, TX, 99 
TL → Localised 
TA → Advanced 
TX → Unknown 
Condensed TNM, N 
ENCR recommendations 
http://www.encr.eu/sites/default/
files/pdf/extentofdisease.pdf 
A2 N 99 Allowed values: N0, N1, NX, 99 
N0 → No regional nodes 
N1 → Regional nodes 
NX → Unknown 
Condensed TNM, M 
ENCR recommendations 
http://www.encr.eu/sites/default/
files/pdf/extentofdisease.pdf 
A2 N 99 Allowed values: M0, M1, MX, 99 
M0 → No distant metastasis 
M1 → Distant metastasis 
MX → Unknown 
 
F: Numeric variable A: Alphanumeric variable Y= yes N= no 
*** If complete date of incidence and/or date of end of follow-up are missing or unknown. 
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Table 1. (cont.) 
 
Variable description Format Mandatory Missing/ un- 
known values 
Allowed values 
Dukes’ stage A1 N 9 Allowed values: A, B, C, D, 9 
A → Dukes’ stage A 
B → Dukes’ stage B 
C → Dukes’ stage C 
D → Dukes’ stage D 
9 → Dukes’ stage unknown 
FIGO stage A3 N 999 Allowed values: 0, I, II, III, IVA, IVB, 
999 
0 → FIGO stage 0 
I → FIGO stage I 
II → FIGO stage II 
III → FIGO stage III 
IVA → FIGO stage IVA 
IVB → FIGO stage IVB 
9 → FIGO stage unknown 
Summary extent of disease 
(EOD) 
F1 N 9 Allowed values: 1, 2, 3, 4, 5, 9 
1 → Confined 
2 → Adjacent tissues, and/or 
regional lymph-nodes 
     3 → Distant organs 
4 → Not confined but not 
specified whether code 2 or 3 
applies 
5 → Not distant metastasis but 
not specified whether code 1 or 
2 applies 
9 → Unknown 
Tumour size in mm with decimal F5 N 999.9 > 0 or 999.9 
Number examined nodes F2 N 99 From 0 to 99 
Number metastatic nodes F2 N 99 Number metastasis nodes ≤ 
Number examined nodes 
Sentinel nodes F1 N 9 Allowed values: 1, 2, 9 
1 → Done 
2 → Not done 
9 → Unknown 
Metastasis in sentinel nodes F1 N 9 Allowed values: 1, 2, 9 
     1 → Yes 
     2 → No 
9 → Unknown 
 
F: Numeric variable A: Alphanumeric variable Y= yes N= no
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Table 1. (cont.) 
 
Variable description Format Mandatory Missing/ un- 
known values 
Allowed values 
C factor 
ENCR recommendations 
http://www.encr.eu/sites/default/
files/pdf/extentofdisease.pdf 
F1 N 9 Allowed values: 1, 2, 3, 4, 5, 9 
1 → C1 Evidence from standard 
diagnostic methods only 
2 → C2 Evidence obtained 
by special diagnostic means 
3 → C3 Evidence from surgical 
exploration, including biopsy 
and cytology 
4 → C4 Evidence following de-
finitive surgery and pathological 
examination of the resected 
specimen 
5 → C5 Evidence from autopsy 
9 → unknown 
Surgery F1 N 9 Allowed values: 1, 2, 9 
1 → Yes 
2 → No 
9 → Unknown 
Chemotherapy F1 N 9 Allowed values: 1, 2, 9 
1 → Yes 
2 → No 
9 → Unknown 
Systemic therapy, other than 
chemotherapy 
F1 N 9 Allowed values: 1, 2, 9 
1 → Yes 
2 → No 
9 → Unknown 
Radiotherapy F1 N 9 Allowed values: 1, 2, 9 
1 → Yes 
2 → No 
9 → Unknown 
Hormone therapy F1 N 9 Allowed values: 1, 2, 9 
1 → Yes 
2 → No 
9 → Unknown 
Bone marrow transplantation F1 N 9 Allowed values: 1, 2, 9 
1 → Yes 
2 → No 
9 → Unknown 
 
F: Numeric variable A: Alphanumeric variable Y= yes N= no
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. List of quality checks: internal consistency 
 
3.1. Consistency within variables 
 
Most of the quality control checks for single 
variables concern its format and allowed val- 
ues, detailed in Table 1. Nevertheless, other 
specific quality checks detailed below are re- 
quired for dates and TNM/stage. 
 
Regarding ‘dates’, some simple rules are nec- 
essary when they are collected as three inde- 
pendent variables reporting ‘day’, ‘month’ 
and ‘year’ (Figure 1): 
 
• if the variable ‘month’ is equal to January 
(01), March (03), May (05), July (07), 
August (08), October (10) or December 
(12) the range of values for the variable 
day is from 1 to 31; 
• if the variable ‘month’ is April (04), June 
(06), September (09) or November (11) the 
range of values for the variable ‘day’ is 
from 1 to 30; 
• if the variable ‘month’ is February (02) 
the range of values for the variable ‘day’ 
is from 1 to 28, except for leap-years in 
which the range of values for the ‘day’ is 
from 1 to 29. The algorithm to define a 
leap-year is the following: 
° it is a year divisible by 4 (i.e. 2004, 2008, 
etc.). This rule does not apply to cen- 
tennial years (those exactly divisible by 
100 (i.e. 1900, 2100, etc.); 
° it is a centennial year (exactly divisible 
by 100) and it is also exactly divisible by 
400 (like 2000, 2400). 
 
 
 
Figure 1. Range of values for the variable ‘day’ according to variables ‘month’ and ‘year’. 
 
 
 
Common year Leap year 
Variable: 'month' 
  = 01, 03, 05, 07, 08, 10 or 12 
Variable: ‘day’ 
Variable: ‘month’ 
= 04, 06, 09 or 11 
Variable: ‘month’ 
= 02 
Range of values: 
from 01 to 31 
Range of values: 
from 01 to 30 Variable: ‘year’ 
Range of values: 
from 01 to 28 
Range of values: 
from 01 to 29 
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Age at diagnosis: measured as the age in years 
at the patient’s last birthday. Age could be 
calculated if both incidence and birth dates 
are registered (or at least the incidence year 
and birth year). It is recommended using al- 
gorithms to impute the dates before calcu- 
lating the age, when possible. The range of 
values must be between 0 and 120. 
 
This variable is optional if at least both in- 
cidence and birth year are available, while it 
is mandatory when at least one of them is 
missing: 
 
• If only year of diagnosis and birth are avail- 
able, then age at diagnosis is computed as 
a difference: 
 
 
 
• If the month and year of both dates are 
known, then age at diagnosis is computed 
as: 
 
 
 
• If the month of diagnosis and birth are 
known and equal, and the day of diagno- 
sis is earlier than the day of birth, then 1 is 
subtracted from the calculated age. 
 
Once computed, the age at diagnosis should 
be compared with what was provided by the 
CRs, and be consistent according to the fol- 
lowing rule: 
TNM and stage grouping values depend on 
the cancer topography and the edition of 
the TNM classification. The TNM system 
includes both clinical (pre-treatment) and 
pathological (post-surgical histopathologi- 
cal) classifications. The clinical classifica- 
tion is designated as cTNM, and the patho- 
logical as pTNM. 
 
Table 2 includes the valid values for T (extent of 
primary tumour), N (absence/presence and 
extent of regional lymph node metastasis) 
and M (absence/presence of distant metas- 
tasis) as well as the corresponding stage by 
topography and revision of TNM classifica- 
tion (6 and 7), according to the case defini- 
tions described in section 2.1 of this report. 
 
T, N and M values are similar for clinical and 
pathological classifications with very few ex- 
ceptions. Therefore, unless clearly specified, 
the T, N and M values included in Table 2 
are valid for both cTNM and pTNM clas- 
sifications. 
 
In addition, Appendices II and III contain 
detailed stage grouping as well as the corre- 
sponding T, N, M values for the TNM 6 and 
TNM 7 editions, respectively. 
 
 
Age at diagnosis = year of incidence - year of birth 
Age at diagnosis = [(year of incidence * 12 + month of 
incidence) - (year of birth * 12 + month of birth)] / 12 
 
Integer 
Age at diagnosis computed 
= registered age at diagnosis ± 1 
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Table 2. Valid values for T, N, M and stage by cancer topography and TNM edition. § 
 
Topography TNM edition T N M Stage grouping 
Lip and oral cavity 
C00, C02-C06 
(except C051 and 
C052) 
6 TX, T1, T2, T3, T4a, 
T4b 
NX, N0, N1, N2, 
N2a, N2b, N2c, N3 
MX, M0, M1 I, II, III, IVA, IVB, IVC 
7 TX, T1, T2, T3, T4a, 
T4b 
NX, N0, N1, N2, 
N2a, N2b, N2c, N3 
M0, M1 I, II, III, IVA, IVB, IVC 
Oropharynx 
C01, C051, C052, 
C090, C091, C099, 
C100, C102, C103 
 
 
 
 
6 
TX, T1, T2, T3, T4a, 
T4b 
NX, N0, N1, N2, 
N2a, N2b, N2c, N3 
 
 
 
 
MX, M0, M1 
I, II, III, IVA, IVB, IVC 
Nasopharynx 
C11 
TX, T1, T2, T2a, 
T2b, T3, T4 
NX, N0, N1, N2, N3, 
N3a, N3b 
I, IIA, IIB, III, IVA, 
IVB, IVC 
Hypopharynx 
C12, C13 
TX, T1, T2, T3, T4a, 
T4b 
NX, N0, N1, N2, 
N2a, N2b, N2c, N3 
I, II, III, IVA, IVB, IVC 
Oropharynx 
C01, C051, C052, 
C090, C091, C099, 
C100, C102, C103 
 
 
 
 
7 
TX, T1, T2, T3, T4a, 
T4b 
NX, N0, N1, N2, 
N2a, N2b, N2c, N3 
 
 
 
 
M0, M1 
 
 
 
 
I, II, III, IVA, IVB, IVC 
Nasopharynx 
C11 
TX, T1, T2, T3, T4 NX, N0, N1, N2, N3, 
N3a, N3b 
Hypopharynx 
C12, C13 
TX, T1, T2, T3, T4a, 
T4b 
NX, N0, N1, N2, 
N2a, N2b, N2c, N3 
Major salivary 
glands 
C07, C08 
6 TX, T1, T2, T3, T4a, 
T4b 
NX, N0, N1, N2, 
N2a, N2b, N2c, N3 
MX, M0, M1 I, II, III, IVA, IVB, IVC 
7 TX, T1, T2, T3, T4a, 
T4b 
NX, N0, N1, N2, 
N2a, N2b, N2c, N3 
M0, M1 I, II, III, IVA, IVB, IVC 
Oesophagus 
C15 
6 TX, T1, T2, T3, T4 NX, N0, N1 MX, M0, M1, M1a 
(for C153 and 
C155), M1b (for 
C153, C154 and 
C155) 
I, IIA, IIB, III, IV, IVA, 
IVB 
Oesophagus 
C15, C160 
7 TX, T1, T2, T3, T4, 
T4a, T4b 
NX, N0, N1, N2, N3 M0, M1 IA, IB, IIA, IIB, IIIA, 
IIIB, IIIC, IV 
Stomach 
C16 
6 TX, T1, T2, T2a, 
T2b, T3, T4 
NX, N0, N1, N2, N3 MX, M0, M1 IA, IB, II, IIIA, IIIB, IV 
Stomach 
C161-C164 
7 TX, T1, T1a, T1b, T2, 
T3, T4, T4a, T4b 
NX, N0, N1, N2, N3, 
N3a, N3b 
M0, M1 IA, IB, IIA, IIB, IIIA, 
IIIB, IIIC, IV 
Small intestine 
C17 
6 TX, T1, T2, T3, T4 NX, N0, N1 MX, M0, M1 I, II, III, IV 
7 TX, T1, T1a, T1b, T2, 
T3, T4 
NX, N0, N1, N2 M0, M1 I, IIA, IIB, IIIA, IIIB, 
IV 
Appendix carcinoma 
C181 
7 TX, Tis, T1, T2, T3, 
T4, T4a, T4b 
NX, N0, N1, N2 M0, M1, M1a, M1b 0, I, IIA, IIB, IIC, IIIA, 
IIIB, IIIC, IVA, IVB, 
IVC 
 
§   In general, the classification applies to carcinomas, except for some topographies with specific morphologies that use separate classifica- 
tions (i.e. appendix-carcinoid). There should be histological confirmation of the disease. 
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Table 2. (cont.) § 
 
Topography TNM edition T N M Stage grouping 
Appendix carcinoid 
C181 
(well differentiated 
neuroendocrine 
tumour) 
7 TX, T1, T1a, T1b, T2, 
T3, T4 
NX, N0, N1 M0, M1 I, II, III, IV 
Colon and rectum 
C18, C19, C20 
6 TX, Tis, T1, T2, T3, 
T4 
NX, N0, N1, N2 MX, M0, M1 0, I, IIA, IIB, IIIA, 
IIIB, IIIC, IV 
Colon and rectum 
C18 (excluded 
C181), C19, C20 
7 TX, Tis, T1, T2, T3, 
T4, T4a, T4b 
NX, N0, N1, N1a, 
N1b, N1c, N2, N2a, 
N2b 
M0, M1, M1a, M1b 0, I, II, IIA, IIB, IIC, 
III, IIIA, IIIB, IIIC, 
IVA, IVB 
Anal canal 
C211 
6 TX, T1, T2, T3, T4 NX, N0, N1, N2, N3 MX, M0, M1 I, II, IIIA, IIIB, IV 
7 TX, T1, T2, T3, T4 NX, N0, N1, N2, N3 M0, M1 I, II, IIIA, IIIB, IV 
Gastrointestinal 
stromal tumour 
(GIST) 
C15, C16, C170, 
C171, C172, C18, 
C20, C481 (Omen- 
tum, mesentery) 
7 TX, T1, T2, T3, T4 NX, N0, N1 M0, M1 C16, C481 
(omental GIST) 
IA, IB, II, IIIA, IIIB, IV 
C17, C15, C18, 
C20, C481 
(mesentery) 
I, II, IIIA, IIIB, IV 
Gastric, small and 
large Intestinal 
carcinoid tumours 
(appendix 
excluded)* 
 
 
 
 
7 
Stomach 
TX, T1, T2, T3, T4 
 
 
 
 
NX, N0, N1 
 
 
 
 
M0, M1 
 
 
 
I, IIA, IIB, IIIA, IIIB, 
IV 
Duodenum, ampul-
la, jejunum, ileum 
TX, T1, T2, T3, T4 
Large intestine       
TX, T1, T1a, T1b, 
T2, T3, T4 
Liver and intra- 
hepatic bile ducts 
C220, C221 
6 TX, T1, T2, T3, T4 NX, N0, N1 MX, M0, M1 I, II, IIIA, IIIB, IIIC, IV 
Liver– hepatocel- 
lular carcinoma 
C220 
 
 
 
7 
TX, T1, T2, T3, T3a, 
T3b, T4 
 
 
 
NX, N0, N1 
 
 
 
M0, M1 
I, II, IIIA, IIIB, IIIC, 
IVA, IVB 
Liver– intrahepatic 
bile ducts 
C221 
TX, T1, T2a, T2b, 
T3, T4 
I, II, III, IVA, IVB 
Gallbladder 
C23 
6 TX, T1, T1a, T1b, T2, 
T3, T4 
NX, N0, N1 MX, M0, M1 IA, IB, IIA, IIB, III, IV 
7 TX, T1, T1a, T1b, T2, 
T3, T4 
NX, N0, N1 M0, M1 I, II, IIIA, IIIB, IVA, 
IVB 
 
§   In general, the classification applies to carcinomas, except for some topographies with specific morphologies that use separate classifica- 
tions (i.e. appendix-carcinoid). There should be histological confirmation of the disease. 
*    Well-differentiated neuroendocrine tumours and Well-differentiated neuroendocrine carcinomas. 
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Table 2. (cont.) § 
 
Topography TNM edition T N M Stage grouping 
Extrahepatic bile 
ducts 
C240 
6 TX, T1, T2, T3, T4 NX, N0, N1 MX, M0, M1 IA, IB, IIA, IIB, III, IV 
7 C240– Perihilar 
TX, T1, T2a, T2b, 
T3, T4 
C240– Distal 
TX, T1, T2, T3, T4 
NX, N0, N1 M0, M1 C240– Perihilar 
I, II, IIIA, IIIB, IVA, 
IVB 
C240– Distal 
IA, IB, IIA, IIB, III, IV 
Ampulla of vater 
C241 
6 TX, T1, T2, T3, T4 NX, N0, N1 MX, M0, M1 IA, IB, IIA, IIB, III, IV 
7 TX, T1, T2, T3, T4 NX, N0, N1 M0, M1 IA, IB, IIA, IIB, III, IV 
Pancreas 
C25 
6 TX, T1, T2, T3, T4 NX, N0, N1 MX, M0, M1 IA, IB, IIA, IIB, III, IV 
7 TX, T1, T2, T3, T4 NX, N0, N1 M0, M1 IA, IB, IIA, IIB, III, IV 
Supraglottis 
C321, C101 
 
 
 
6 
TX, T1, T2, T3, T4a, 
T4b 
 
 
NX, N0, N1, N2, 
N2a, N2b, N2c, N3 
 
 
 
MX, M0, M1 
 
 
 
I, II, III, IVA, IVB, IVC 
Glottis 
C320 
TX, T1, T1a, T1b, T2, 
T3, T4a, T4b 
Subglottis 
C322 
TX, T1, T2, T3, T4a, 
T4b 
Supraglottis 
C321, C101 
 
 
 
7 
TX, T1, T2, T3, T4a, 
T4b 
 
 
NX, N0, N1, N2, 
N2a, N2b, N2c, N3 
 
 
 
M0, M1 
 
 
 
I, II, III, IVA, IVB, IVC 
Glottis 
C320 
TX, T1, T1a, T1b, T2, 
T3, T4a, T4b 
Subglottis 
C322 
TX, T1, T2, T3, T4a, 
T4b 
Nasal cavity and 
paranasal sinuses 
C300, C310, C311 
6 TX, T1, T2, T3, T4a, 
T4b 
NX, N0, N1, N2, 
N2a, N2b, N2c, N3 
MX, M0, M1 I, II, III, IVA, IVB, IVC 
7 TX, T1, T2, T3, T4a, 
T4b 
NX, N0, N1, N2, 
N2a, N2b, N2c, N3 
M0, M1 I, II, III, IVA, IVB, IVC 
Malignant 
melanoma of 
aerodigestive tract 
(C00-C06, C10- 
C14, C30-C32) 
7 TX, T3, T4a, T4b NX, N0, N1 M0, M1 III, IVA, IVB, IVC 
Lung 
C34 
6 TX, T1, T2, T3, T4 NX, N0, N1, N2, N3 MX, M0, M1 IA, IB, IIA, IIB, IIIA, 
IIIB, IV 
7 TX, T1, T1a, T1b, T2, 
T2a, T2b, T3, T4 
NX, N0, N1, N2, N3 M0, M1, M1a, M1b IA, IB, IIA, IIB, IIIA, 
IIIB, IV 
Pleural 
mesothelioma 
C384 
6 TX, T1, T1a, T1b, T2, 
T3, T4 
NX, N0, N1, N2, N3 MX, M0, M1 IA, IB, II, III, IV 
7 TX, T1, T1a, T1b, T2, 
T3, T4 
NX, N0, N1, N2, N3 M0, M1 IA, IB, II, III, IV 
 
§   In general, the classification applies to carcinomas, except for some topographies with specific morphologies that use separate classifica- 
tions (i.e. appendix-carcinoid). There should be histological confirmation of the disease. 
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Table 2. (cont.) § 
 
Topography TNM edition T N M Stage grouping 
Bone 
C40, C41 
6 TX, T1, T2, T3 NX, N0, N1 MX, M0, M1, M1a, 
M1b 
IA, IB, IIA, IIB, III, 
IVA, IVB 
7 TX, T1, T2, T3 NX, N0, N1 M0, M1, M1a, M1b IA, IB, II, III, IVA, IVB 
Soft tissues 
C381, C382, C383, 
C47, C480, C49, 
9581/3, 8804/3, 
9220/3, 9180/3, 
9260/3, 9473/3, 
8810/3, 8890/3, 
8850/3, 8830/3, 
9150/3, 8990/3, 
9540/3, 8900/3, 
9040/3, 8800/3 
6** TX, T1, T1a, T1b, T2, 
T2a, T2b 
NX, N0, N1 MX, M0, M1 IA, IB, IIA, IIB, III, IV 
7*** TX, T1, T1a, T1b, T2, 
T2a, T2b 
NX, N0, N1 M0, M1 I, IIA, IIB, III, IV 
Carcinoma of eyelid 
C441 
6 TX, T1, T2, T3, T4 NX, N0, N1 MX, M0, M1 No stage grouping 
recommended 
7 TX, T1, T2a, T2b, 
T3a, T3b, T4 
NX, N0, N1 M0, M1 IA, IB, IC, II, IIIA, 
IIIB, IIIC, IV 
Carcinoma 
of conjunctiva 
C690 
6 TX, T1, T2, T3, T4, 
T4a, T4b, T4c, T4d 
NX, N0, N1 MX, M0, M1 No stage grouping 
recommended 
7 TX, T1, T2, T3, T4, 
T4a, T4b, T4c, T4d 
NX, N0, N1 M0, M1 No stage grouping 
recommended 
Malignant 
melanoma of 
conjunctiva 
C690 
6 TX, T1, T2, T3, T4 NX, N0, N1 MX, M0, M1 No stage grouping 
recommended 
7 TX, T1, T1a, T1b, 
T1c, T1d, T2, T2a, 
T2b, T2c, T2d, T3, 
T3a, T3b, T3c, T3d, 
T4 
NX, N0, N1 M0, M1 No stage grouping 
recommended 
Malignant 
melanoma of uvea 
C693, C694 
6 TX, T1, T1a, T1b, 
T1c, T2, T2a, T2b, 
T2c, T3, T3a, T4 
NX, N0, N1 MX, M0, M1 I, II, III, IV 
7 TX, T1, T1a, T1b, 
T1c, T1d, T2, T2a, 
T2b, T2c, T2d, T3, 
T3a, T3b, T3c, T3d, 
T4, T4a, T4b, T4c, 
T4d, T4e 
NX, N0, N1 M0, M1 I, IIA, IIB, IIIA, IIIB, 
IIIC, IV 
§ In general, the classification applies to carcinomas, except for some topographies with specific morphologies that use separate classifica- 
tions (i.e. appendix-carcinoid). There should be histological confirmation of the disease. 
** The following histological types are not included: Kaposi sarcoma, dermatofibrosarcoma (protuberans), fibromatosis (desmoid tu- 
mour), and sarcoma arising from the dura mater, brain, hollow viscera or parenchymatous organs (with the exception of breast sarcomas) 
and angiosarcoma. 
*** The following histological types are not included: Kaposi sarcoma, dermatofibrosarcoma (protuberans), fibromatosis (desmoid tu- 
mour), sarcoma arising from the dura mater, brain, hollow viscera or parenchymatous organs (with the exception of breast sarcomas), 
angiosarcoma and gastrointestinal stromal tumours. 
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Table 2. (cont.) § 
 
Topography TNM edition T N M Stage grouping 
Sarcoma of orbit 
C696 
6 TX, T1, T2, T3, T4 NX, N0, N1 MX, M0, M1 No stage grouping 
recommended 
7 TX, T1, T2, T3, T4 NX, N0, N1 M0, M1 No stage grouping 
recommended 
Carcinoma 
of lachrymal gland 
C695 
6 TX, T1, T2, T3, T3a, 
T3b, T4 
NX, N0, N1 MX, M0, M1 No stage grouping 
recommended 
7 TX, T1, T2, T3, T4, 
T4a, T4b, T4c 
NX, N0, N1 M0, M1 No stage grouping 
recommended 
Retinoblastoma 
C692 
6 Clinical T 
TX, T1, T1a, T1b, 
T2, T2a, T2b, T2c, 
T3, T4 
Pathological T 
pTX, pT0, pT1, pT2, 
pT2a, pT2b, pT2c, 
pT3, pT3a, pT3b, 
pT3c, pT4 
NX, N0, N1 Clinical M 
MX, M0, M1 
Pathological M 
pMX, pM0, pM1, 
pM1a, pM1b 
No stage grouping 
recommended 
7 Clinical T 
TX, T1, T1a, T1b, 
T1c, T2, T2a, T2b, 
T3, T3a, T3b, T4, 
T4a, T4b, T4c, T4d 
Pathological T 
pTX, pT0, pT1, pT2, 
pT2a, pT2b, pT2c, 
pT3, pT3a, pT3b, 
pT3c, pT4 
Clinical N 
NX, N0, N1 
Pathological N 
pNX, pN0, pN1, 
pN2 
Clinical M 
M0, M1 
Pathological M 
pM0, pM1, pM1a, 
pM1b, pM1c, pM1d, 
pM1e 
No stage grouping 
recommended 
Carcinoma of skin 
C440, C442-C447, 
C632 
6 TX, T1, T2, T3, T4 NX, N0, N1 MX, M0, M1 I, II, III, IV 
7 TX, T1, T2, T3, T4 NX, N0, N1, N2, N3 M0, M1 I, II, III, IV 
Malignant 
melanoma of skin 
C44, C510, C609, 
C632 
6 Extent of tumour 
is classified after 
excision: 
pTX, pTis, pT1, 
pT1a, pT1b, pT2, 
pT2a, pT2b, pT3, 
pT3a, pT3b, pT4, 
pT4a, pT4b 
NX, N0, N1, N1a, 
N1b, N2, N2a, N2b, 
N2c, N3 
MX, M0, M1, M1a, 
M1b, M1c 
0, I, IA, IB, IIA, IIB, 
IIC, III, IIIA, IIIB, 
IIIC, IV 
7 Extent of tumour 
is classified after 
excision: 
pTX, pTis, pT1, 
pT1a, pT1b, pT2, 
pT2a, pT2b, pT3, 
pT3a, pT3b, pT4, 
pT4a, pT4b 
NX, N0, N1, N1a, 
N1b, N2, N2a, N2b, 
N2c, N3 
M0, M1, M1a, M1b, 
M1c 
0, I, IA, IB, IIA, IIB, 
IIC, III, IIIA, IIIB, 
IIIC, IV 
§   In general, the classification applies to carcinomas, except for some topographies with specific morphologies that use separate classifica- 
tions (i.e. appendix-carcinoid). There should be histological confirmation of the disease. 
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Topography TNM edition T N M Stage grouping 
Merkel cell 
carcinoma of kin 
C44, C632 
7 TX, T1, T2, T3, T4 NX, N0, N1, N1a, 
N1b, N2 
M0, M1, M1a, M1b, 
M1c 
I, IA, IB, IIA, IIB, IIC, 
IIIA, IIIB, IV 
Vulva 
C51 
6 TX, T1, T1a, T1b, T2, 
T3, T4 
NX, N0, N1, N2 MX, M0, M1 I, IA, IB, II, III, IVA, 
IVB 
7 TX, T1, T1a, T1b, 
T2, T3 
NX, N0, N1, N1a, 
N1b, N2, N2a, N2b, 
N2c, N3 
M0, M1 I, IA, IB, II, IIIA, IIIB, 
IIIC, IVA, IVB 
Vagina 
C52 
6 TX, T1, T2, T3, T4 NX, N0, N1 MX, M0, M1 I, II, III, IVA, IVB 
7 TX, T1, T2, T3, T4 NX, N0, N1 M0, M1 I, II, III, IVA, IVB 
Cervix uteri 
C53 
6 TX, Tis, T1, T1a, 
T1a1, T1a2, T1b, 
T1b1, T1b2, T2, 
T2a, T2b, T3, T3a, 
T3b, T4 
NX, N0, N1 MX, M0, M1 0, IA, IA1, IA2, IB, 
IB1, IB2, IIA, IIB, 
IIIA, IIIB, IVA, IVB 
7 TX, Tis, T1, T1a, 
T1a1, T1a2, T1b, 
T1b1, T1b2, T2, 
T2a, T2a1, T2a2, 
T2b, T3, T3a, T3b, 
T4 
NX, N0, N1 M0, M1 0, I, IA, IA1, IA2, IB, 
IB1, IB2, II, IIA, IIA1, 
IIA2, IIB, III, IIIA, 
IIIB, IVA, IVB 
Corpus uteri 
C541, C55 
6 TX, T1, T1a, T1b, 
T1c, T2, T2a, T2b, 
T3, T3a, T3b, T4 
NX, N0, N1 MX, M0, M1 IA, IB, IC, IIA, IIB, 
IIIA, IIIB, IIIC, IVA, 
IVB 
7 TX, T1, T1a, T1b, T2, 
T3, T3a, T3b, T4 
NX, N0, N1 M0, M1 IA, IB, II, IIIA, IIIB, 
IIIC, IVA, IVB 
Uterine sarcoma 
C53, C540, C543 
(8890/3, 8930/3, 
8933/3) 
7 8890/3, 8930/3 
T1, T1a, T1b, T2, 
T2a, T2b, T3, T3a, 
T3b, T4 
8933/3 
T1, T1a, T1b, T1c, 
T2, T2a, T2b, T3, 
T3a, T3b, T4 
NX, N0, N1 M0, M1 I, IA, IB, IC (only for 
8993/3), II, IIA, IIB, 
IIIA, IIIB, IIIC, IVA, 
IVB 
Ovary 
C56 
6 TX, T1, T1a, T1b, 
T1c, T2, T2a, T2b, 
T2c, T3, T3a, T3b 
NX, N0, N1 MX, M0, M1 IA, IB, IC, IIA, IIB, 
IIC, IIIA, IIIB, IIIC, IV 
7 TX, T1, T1a, T1b, 
T1c, T2, T2a, T2b, 
T2c, T3, T3a, T3b, 
T3c 
NX, N0, N1 M0, M1 IA, IB, IC, IIA, IIB, 
IIC, IIIA, IIIB, IIIC, IV 
 
§   In general, the classification applies to carcinomas, except for some topographies with specific morphologies that use separate classifica- 
tions (i.e. appendix-carcinoid). There should be histological confirmation of the disease. 
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Topography TNM edition T N M Stage grouping 
Fallopian tube 
C570 
6 TX, T1, T1a, T1b, 
T1c, T2, T2a, T2b, 
T2c, T3, T3a, T3b, 
T3c 
NX, N0, N1 MX, M0, M1 IA, IB, IC, IIA, IIB, 
IIC, IIIA, IIIB, IIIC, IV 
7 TX, T1, T1a, T1b, 
T1c, T2, T2a, T2b, 
T2c, T3, T3a, T3b, 
T3c 
NX, N0, N1 M0, M1 IA, IB, IC, IIA, IIB, 
IIC, IIIA, IIIB, IIIC, IV 
Gestational 
trophoblastic 
tumours C58 
6 TX, T1, T2 – MX, M0, M1, M1a, 
M1b 
I, IA, IB, II, IIA, IIB, 
III, IIIA, IIIB, IV, IVA, 
IVB 
7 TX, T1, T2 – M0, M1, M1a, M1b I, IA, IB, II, IIA, IIB, 
III, IIIA, IIIB, IV, IVA, 
IVB 
Breast 
C50 
6 TX, Tis, T1, T1mic, 
T1a, T1b, T1c, T2, 
T3, T4, T4a, T4b, 
T4c, T4d 
NX, N0, N1, N2, 
N2a, N2b, N3, N3a, 
N3b, N3c 
Pathological N: 
pNX, pN0, pN1, 
pN1mi, pN1a, 
pN1b, pN1c, pN2, 
pN2a, pN2b, pN3, 
pN3a, pN3b, pN3c 
MX, M0, M1 0, I, IIA, IIB, IIIA, 
IIIB, IIIC, IV 
7 TX, Tis, T0, T1, 
T1mi, T1a, T1b, 
T1c, T2, T3, T4, 
T4a, T4b, T4c, 
T4d 
NX, N0, N1, N2, 
N2a, N2b, N3, N3a, 
N3b, N3c 
Pathological N: 
pNX, pN0, pN1, 
pN1mi, pN1a, 
pN1b, pN1c, pN2, 
pN2a, pN2b, pN3, 
pN3a, pN3b, pN3c 
M0, M1 0, IA, IB, IIA, IIB, 
IIIA, IIIB, IIIC, IV 
Penis 
C60 
6 TX, T1, T2, T3, T4 NX, N0, N1, N2, N3 MX, M0, M1 I, II, III, IV 
7 TX, T1, T1a, T1b, T2, 
T3, T4 
NX, N0, N1, N2, N3 M0, M1 I, II, IIIA, IIIB, IV 
Prostate 
C61 
6 TX, T1, T1a, T1b, 
T1c, T2, T2a, T2b, 
T2c, T3, T3a, T3b, 
T4 
NX, N0, N1 MX, M0, M1, M1a, 
M1b, M1c 
I, II, III, IV 
7 TX, T1, T1a, T1b, 
T1c, T2, T2a, T2b, 
T2c, T3, T3a, T3b, 
T4 
NX, N0, N1 M0, M1, M1a, M1b, 
M1c 
I, II, III, IV 
 
§   In general, the classification applies to carcinomas, except for some topographies with specific morphologies that use separate classifica- 
tions (i.e. appendix-carcinoid). There should be histological confirmation of the disease. 
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Table 2. (cont.) § 
 
Topography TNM edition T N M Stage grouping 
Testis 
C62 
6 Extent of tumour 
→ after radical 
orchiectomy 
pTX, pT1, pT2, pT3, 
pT4 
NX, N0, N1, N2, N3 MX, M0, M1, M1a, 
M1b 
I, IA, IB, IS, II, IIA, 
IIB, IIC, III, IIIA, IIIB, 
IIIC 
7 Extent of tumour 
→ after radical or- 
chiectomy, except 
for T4 
pTX, pT1, pT2, pT3, 
pT4 
NX, N0, N1, N2, N3 M0, M1, M1a, M1b I, IA, IB, IS, II, IIA, 
IIB, IIC, III, IIIA, IIIB, 
IIIC 
Kidney 
C64 
6 TX, T1, T1a, T1b, 
T2, T3, T3a, T3b, 
T3c, T4 
NX, N0, N1, N2 MX, M0, M1 I, II, III, IV 
7 TX, T1, T1a, T1b, T2, 
T2a, T2b, T3, T3a, 
T3b, T3c, T4 
NX, N0, N1 M0, M1 I, II, III, IV 
Renal pelvis 
and ureter 
C65, C66 
6 TX, T1, T2, T3, T4 NX, N0, N1, N2, N3 MX, M0, M1 I, II, III, IV 
7 TX, T1, T2, T3, T4 NX, N0, N1, N2, N3 M0, M1 I, II, III, IV 
Urinary bladder 
C67 
6 TX, Ta, Tis, T1, T2, 
T2a, T2b, T3, T3a, 
T3b, T4, T4a, T4b 
NX, N0, N1, N2, N3 MX, M0, M1 0a, 0is, I, II, III, IV 
7 TX, Ta, Tis, T1, T2, 
T2a, T2b, T3, T3a, 
T3b, T4, T4a, T4b 
NX, N0, N1, N2, N3 M0, M1 0a, 0is, I, II, III, IV 
Urethra (C680) 
and transitional 
cell carcinomas 
of prostate (C619) 
6 TX, T1, T2, T3, T4 NX, N0, N1, N2 MX, M0, M1 I, II, III, IV 
7 TX, T1, T2, T3, T4 NX, N0, N1, N2 M0, M1 I, II, III, IV 
 
§   In general, the classification applies to carcinomas, except for some topographies with specific morphologies that use separate classifica- 
tions (i.e. appendix-carcinoid). There should be histological confirmation of the disease. 
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Table 2. (cont.) § 
 
Topography TNM edition T N M Stage grouping 
Thyroid gland 
C73 
6 TX, T1, T2, T3, T4a, 
T4b 
NX, N0, N1, N1a, 
N1b 
MX, M0, M1 Papillary/Follicular 
<45 years 
I, II 
Papillary/Follicular 
45 years and older 
Medullary 
I, II, III, IVA, IVB, IVC 
Anaplastic/ 
Undifferentiated 
IVA, IVB, IVC 
7 TX, T1, T1a, T1b, T2, 
T3, T4a, T4b 
NX, N0, N1, N1a, 
N1b 
M0, M1 Papillary/Follicular 
<45 years 
I, II 
Papillary/Follicular 
45 years and 
Medullary 
I, II, III, IVA, IVB, IVC 
Anaplastic/ 
Undifferentiated 
IVA, IVB, IVC 
Adrenal cortex 
tumours (C740) 
7 TX, T1, T2, T3, T4 NX, N0, N1 M0, M1 I, II, III, IV 
 
§   In general, the classification applies to carcinomas, except for some topographies with specific morphologies that use separate classifica- 
tions (i.e. appendix-carcinoid). There should be histological confirmation of the disease. 
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3.2. Consistency between variables 
 
3.2.1. Coherence between dates 
 
The following three dates are included in the 
list of agreed upon variables: date of birth, 
date of incidence and date of the last known vital 
status. The proposed rules below check for 
coherence between these dates: 
 
• Date of birth Date of incidence. 
This rule is valid unless the case was diag- 
nosed in utero if the diagnosis is in utero, 
the difference in months between dates 
should be no more than nine. 
• Date of birth Date of the last known 
vital status. 
• Date of incidence  Date of the last 
known vital status. 
 
For each comparison between dates, if years 
are known but month(s) is (are) unknown / 
missing, then the years are only compared. 
Similarly, if the day(s) is (are) unknown/miss- 
ing, only the years and months are compared. 
3.2.2. Consistency between tumour data 
and demographic information 
 
• Consistency between age/topography/ 
morphology. 
 
Some cancers occur almost exclusively in 
certain age groups such as retinoblastoma 
(tumour of young children) or prostate 
cancer in older men; therefore, some 
combinations age/topography/morpholo- 
gy are unlikely and should result in a 
warning. 
 
Nevertheless there are other age and tu- 
mour type combinations that are not un- 
likely but rare. A warning for these com- 
binations improves the precision of these 
rare tumours. After the confirmation by 
CRs, a flag will show that the case has 
been checked. Table 3 shows unlikely and 
rare combinations by age group and tu- 
mour type. 
 
Table 3. Unlikely and rare combinations of age and tumour type. 
 
Age group [years] Morphology Topography 
0-2 Hodgkin lymphoma: 9650-9667 – 
> 9 Neuroblastoma and ganglioneuroblastoma: 9490, 9500 – 
> 5 Retinoblastoma:  9510-9514 – 
> 8 Wilms’ tumour, rhabdoid, and clear 
cell sarcoma 
8960, 8964 – 
8963 C649 
0-8 Renal carcinoma: 8010-8041, 8050-8075, 8082, 8120-8122, 8130-8141, 
8143, 8155, 8190-8201, 8210, 8211, 8221-8231, 8240, 8241, 8244-8246, 
8260-8263, 8290, 8310, 8320, 8323, 8401, 8430, 8440, 8480-8490, 8504, 
8510, 8550, 8560-8573 
C649 
8312 – 
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Table 3. (cont.) 
 
Age group [years] Morphology Topography 
> 5 Hepatoblastoma: 8970 – 
0-8 Hepatic carcinoma 8010-8041, 8050-8075, 8082, 
8120-8122, 8140, 8141, 8143, 8155, 
8190-8201, 8210, 8211, 8230, 8231, 
8240, 8241, 8244-8246, 8260- 
8263, 8310, 8320, 8323, 8401, 
8430, 8440, 8480-8490, 8504, 
8510, 8550, 8560-8573 
C220, C221 
8160-8180 – 
0-5 Osteosarcomas: 9180-9187, 9192-9195 – 
0-5 Chondrosarcoma 9220-9230  
9240 C400-C419 
0-3 Ewing sarcoma: 9260, 9364 – 
> 7 Malignant extra-cranial and extra-gonadal germ cell: 9060-9065, 9070-
9072, 9080-9085, 9100-9105 
C00-C55, C57-C61, 
C63-C69, C73-C750, 
C754-C768, C80 
0-14 Gonadal carcinoma 8010-8041, 8050-8075, 8082, 8120- 
8122, 8130-8141, 8143, 8190-8201, 
8210, 8211, 8221-8241, 8244-8246, 
8260-8263, 8290, 8310, 8320, 
8323, 8380-8384, 8430, 8440, 
8480-8490, 8504, 8510, 8550, 
8560-8573, 9014, 9015 
C56, C62 
8313, 8441, 8450, 8460-8471, 9000 – 
0-5 Thyroid carcinoma 8010-8041, 8050-8075, 8082, 8120- 
8122, 8130-8141, 8155, 8190, 8200, 
8201, 8211, 8230, 8231, 8244-8246, 
8260-8263, 8290, 8310, 8320, 
8323, 8430, 8440, 8480, 8481, 
8510, 8560-8573 
C73 
8330-8337, 8340-8347, 8350 – 
0-5 Nasopharyngeal carcinoma: 8010-8041, 8050-8075, 8082, 8083, 8120- 
8122, 8130-8141, 8190, 8200, 8201, 8211, 8230, 8231, 8244-8246, 8260- 
8263, 8290, 8310, 8320, 8323, 8430, 8440, 8480, 8481, 8500-8576 
C11 
0-4 Skin carcinoma: 8010-8041, 8050-8075, 8078, 8082, 8090-8110, 8140, 
8143, 8147, 8190, 8200, 8240, 8246, 8247, 8260, 8310, 8320, 8323, 8390- 
8420, 8430, 8480, 8542, 8560, 8570-8573, 8940, 8941 
C44 
0-4 Carcinoma, NOS: 8010-8084, 8120-8157, 8190-8264, 8290, 8310, 8314- 
8315, 8320-8325, 8380-8384, 8430-8440, 8452-8454, 8480-8586, 8588- 
8589, 8940-8941, 9000, 9010-9016, 9020, 9030 
C00-C10, C12-C21, 
C23-C39, C48, 
C50-C55, C57-C61, 
C63, C65-C72, 
C75-C76, C80 
0-14 Mesothelial neoplasms: 9050-9053 Any 
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Table 3. (cont.) 
 
Age group [years] Morphology Topography 
0-14 Any C17, C25 
0-14 Choriocarcinoma: 9100 Any 
< 20 Any C15, C19, C20, 21, 
C23, C24, C384, 
C50-C55 
Less than 9590 (Haematological malignancies) C17 
Any other than carcinoid tumours (8240-8245) C18, C33, C34 
< 25 Multiple myeloma: 9732 and Chronic lymphocytic leukaemia: 9823 Any 
< 30 Chronic myeloid leukaemia: 9876, 9945 Any 
Any C60 
< 40 Adenocarcinoma: 8140 C61 
> 45 Choriocarcinoma: 9100 C58 
> 14 8910, 8960, 8970, 8981, 8991, 9072, 9470, 951_, 9687 Any 
Juvenile myelomonocytic leukaemia: 9946 Any 
 
 
• Consistency between sex/topography. 
 
Some sex /topography combinations are 
impossible. Invalid combinations are pre- 
sented in Table 4. 
 
Table 4. Invalid sex and topography combinations. 
 
Sex = 1 (male) Sex = 2 (female) 
C51   Vulva C60   Penis 
C52   Vagina C61   Prostate gland 
C53   Cervix uteri C62   Testis 
C54   Corpus uteri C63   Other and unspecified male genital organs 
C55   Uterus, NOS  
C56   Ovary  
C57   Other and unspecified female genital organs  
C58   Placenta  
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• Consistency between sex/morphology. 
 
Table 5 includes a list of unlikely sex /mor- 
phology combinations. 
 
Table 5. Unlikely sex and morphology combinations. 
 
Sex = 1 (male) Sex= 2 (female) 
8313/3   Clear cell adenocarcinofibroma 9061/3   Seminoma, NOS 
8380/3   Endometrioid adenocarcinoma, NOS 9062/3   Seminoma, anaplastic 
8381/3   Endometrioid adenofibroma, malignant 9063/3   Spermatocytic seminoma 
8382/3   Endometrioid adenocarcinoma, secretory variant  
8383/3   Endometrioid adenocarcinoma, ciliated cell variant  
8384/3   Adenocarcinoma, endocervical type  
8441/3   Serous cystadenocarcinoma, NOS  
8460/3   Papillary serous cystadenocarcinoma  
8471/3   Papillary mucinous cystadenocarcinoma  
8482/3   Mucinous adenocarcinoma, endocervical type  
8600/3   Thecoma, malignant  
8670/3   Steroid cell tumour, malignant  
8930/3   Endometrial stromal sarcoma, NOS  
8931/3   Endometrial stromal sarcoma, low grade  
8934/3   Carcinofibroma  
8950/3   Mullerian mixed tumour  
8951/3   Mesodermal mixed tumour  
9000/3   Brenner tumour, malignant  
9014/3   Serous adenocarcinofibroma  
9015/3   Mucinous adenocarcinofibroma  
9090/3   Struma ovary, malignant  
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Basis of diagnosis (BoD) 
BoD = 0 BoD = 1 BoD = 2 BoD = 4 
BoD = 5* 
or BoD = 7* 
BoD = 6 BoD = 9 
3.2.3. Consistency between tumour variables 
 
• Consistency between basis of diagnosis/mor- 
phology/behaviour. 
 
It is unlikely for specific morphologies not 
to have undergone a histological /cyto- 
logical examination. Nevertheless, some 
combinations are considered as excep- 
tions. ENCR recommendations have been 
followed for ‘specific’ morphology codes 
in absence of microscopic verification. 
Morphology codes for cases with ‘death 
certificate only’ (DCO) are allowed when 
they can be identified from the underly- 
ing cause of death code (International 
Classification of Diseases 10th Revision). 
 
Figure 2 shows the accepted combinations 
between basis of diagnosis (BoD) and 
morphology. Combinations not included 
in Figure 2 need to be verified. 
 
Figure 2. Valid combinations for basis of diagnosis and morphology. 
 
 
 
 
 
 
 
 
 
 
 Morphology: 
 
Morphology: 
 
Morphology: 
 
     Morphology: 
 
     Morphology 
 
     Morphology 
 
Morphology 
  8000, 8272, 8000, 8720, 8000, 8720,      8000, 8150-      included      included included in 
8720, 8970, 9140, 9590, 8800, 8960      8154, 8170, in ICD-O-3      in ICD-O-3 ICD-O-3 
9050, 9065, 9800 (age 0-8),      8270-8281 and ≠ 8000;      and ≠ 8000;  
9100, 9140,  9140, 9380      (C751), 9100 ≠ 8001;      9590-9731;  
9510, 9530,  (C717),      (female age ≠ 9590;      ≠ 9732;  
9560, 9590,  9384/1      15-49), 9500 ≠ 9800;      ≠ 9733-  
9591-9731,  (tuberous      (age 0-9), ≠ 9820;      9760;  
9732,  sclerosis      9732 (and ≠ 9960      ≠ 9761;  
9733-9760,  patient),      age 40+),       ≠ 9762-  
9761,  9500 (age      9761 (and       9992  
9762-9992  0-9), 9510      age 50+)    
  (age 0-5),     
  9530-9539 
(C70), 9590, 
9800 
    
 
*  Since the determination that a neoplasm has not invaded surrounding tissue (in situ) is made via the microscope, cases coded in situ 
(behaviour = 2) should have a basis of diagnosis = 7 or 5. 
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• Consistency between morphology/grade. 
 
Only malignant tumours (behaviour = 3) 
should be graded. The combination be- 
tween a ‘behaviour’ code less than 3 and a 
‘grade’ code less than 9 will be considered 
as an error. 
This edit is skipped if ‘grade’ is blank or 
missing. 
 
Grade values and the allowed corresponding 
morphology codes are shown in Table 6. 
 
 
 
Table 6. Valid combinations for morphology and grade. 
 
Grade → 5 6 8 
Morphology 9700-9702, 9705, 9708, 
9709, 9714, 9716, 9717, 
9718, 9719, 9724, 9725, 
9726, 9729, 9800, 9801, 
9805-9807, 9809, 9820, 
9827, 9831, 9834, 9837 
9591, 9596, 9597, 9670, 
9671, 9673, 9678-9680, 
9684, 9687-9691, 9695, 
9698, 9699, 9712, 9728, 
9731, 9732, 9734, 9737, 
9738, 9762, 9800, 9801, 
9805-9808, 9811, 9812- 
9818, 9820, 9823, 9826, 
9833, 9836, 9940 
9719, 9727, 9831, 9948 
 
 
The combination between grades 5-8 
and morphology out of the range 9590-
9992 is impossible.
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Some terms in ICD-O-3 carry an implied 
statement of grade; therefore an appro-
priate grade code needs to be associated. 
 These combinations are specified in the 
following Table 7. 
 
Table 7. Morphology code and description, and correct associated grade for ICD-O-3 terms with implied statement of grade. 
 
Morphology code Morphology description Grade 
8020/3 Carcinoma, undifferentiated, NOS 4 
8021/3 Carcinoma, anaplastic, NOS 4 
8240/3 Neuroendocrine carcinoma, well-differentiated 1 
8249/3 Neuroendocrine carcinoma, moderately differentiated 2 
8331/3 Follicular adenocarcinoma, well-differentiated 1 
8332/3 Follicular adenocarcinoma, moderately differentiated 2 
8585/3 Well-differentiated thymic carcinoma 1 
8631/3 Sertoli-Leydig cell tumour, poorly differentiated 3 
8634/3 Sertoli-Leydig cell tumour, poorly differentiated, with heterologous elements 3 
8805/3 Undifferentiated sarcoma 4 
8851/3 Liposarcoma, well-differentiated 1 
9062/3 Seminoma, anaplastic 4 
9082/3 Malignant teratoma, undifferentiated 4 
9362/3 Pineal parenchymal tumour of intermediate differentiation 2, 3 
9382/3 Anaplastic oligoastrocytoma 3 
9390/3 Choroid plexus papilloma, anaplastic 3 
9401/3 Astrocytoma, anaplastic 3 
9440/3 Glioblastoma 4 
9451/3 Oligodendroglioma, anaplastic 3 
9511/3 Retinoblastoma, differentiated 1 
9512/3 Retinoblastoma, undifferentiated 4 
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• Consistency between topography/laterality. 
 
‘Laterality’ that means ‘bilateral and sepa- 
rated topographies’ should be coded for 
those paired organs for which such in- 
formation may be relevant for clinical or 
epidemiological reasons. Therefore, later- 
ality has a valid code from 1 to 4 for only 
the following topographies: 
 
List of paired organs for which it is suggested to 
collect laterality: 
 
• C07 Parotid gland 
• C09 Tonsil 
• C300 Nasal cavity 
• C340, C341, Lung 
C343, C348,   
C349 
• C384 Pleura 
• C400 Long bones of upper limb 
and scapula 
• C401 Short bones of upper limb 
• C402 Long bones of lower limb 
• C403 Short bones of lower limb 
• C413 Rib and clavicle 
• C414 Pelvic bones (excluding sa- 
crum, coccyx, and symphy- 
sis pubis) 
• C441 Skin of eyelid 
• C442 Skin of external ear 
• C446 Skin of arm and shoulder 
• C447 Skin of leg and hip 
• C50 Breast 
• C56 Ovary 
• C570 Fallopian tube 
• C62 Testis 
• C630 Epididymis 
• C649 Kidney 
 
• C570 Fallopian tube 
• C62 Testis 
• C630 Epididymis 
• C649 Kidney 
• C659 Renal pelvis 
• C66 Ureter 
• C69 Eye 
• C74 Suprarenal gland 
 
Laterality is usually 1 for the topography 
C342, except for rare cases with situs inversus. 
 
 
 
• Consistency between topography/morpho- 
logy. 
 
The topography/ morphology combina- 
tions include those morphologies com- 
monly identified in specific primary topog- 
raphy (allowed topography codes) as well 
as the ones occurring only rarely or never 
in some specific primary topographies (not 
allowed topography codes). Table 8 reports 
allowed/ refused combinations. 
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Table 8. Morphology codes and allowed/refused topography codes. 
 
Morphology codes Allowed topography codes Not allowed topography codes 
8000-8005  C420, C421, C77 
8010-8589  C38, C40-C42, C47, C480, C49, C70- 
C72, C77 
8015 C53  
8077 C00-C15, C21, C30-C32, C44, C51- 
C53, C60 
 
8080 C51, C60  
8081 C00, C300, C44, C51, C60, C632, 
C690, C691 
 
8082 C00-C14, C16, C30-C34, C44, C53, 
C65-C68, C80 
 
8090-8095, 8097, 8100-8103, 8110 C300, C44, C51, C60, C632  
8098 C53  
8120, 8122, 8130, 8131 C56, C65-C68, C80  
8121 C300, C31, C65-C68  
8124 C212  
8142 C16  
8144 C15-C26, C30, C31, C52, C53, C56, 
C67, C80 
 
8145 C15-C20, C80  
8147 C00-C14, C30-C32, C50, C61  
8148 C15-C25, C61  
8150-8152, 8154, 8155 C25  
8153 C16, C170, C25, C80  
8156 C170, C25, C80  
8160, 8161 C221, C239, C240  
8162 C240  
8163 C22-C25  
8170-8175 C220  
8180 C221, C220  
8201 C15-C26, C50, C61, C80  
8210 C15-C26  
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Table 8. (cont.) 
 
Morphology codes Allowed topography codes Not allowed topography codes 
8211 C15-C26, C50, C61, C80  
8213 C18  
8214 C16  
8215 C211  
8220, 8221 C18-C20  
8243 C18, C56, C80  
8247 C300, C44, C51, C60, C632, C80  
8250-8254 C34  
8261, 8262 C15-C26, C52-C57  
8263 C15-C26, C52-C57, C64  
8265 C18-C20  
8270-8272, 8280, 8281, 8300 C751  
8290 C07, C08, C64, C73, C740, C751, C80  
8312, 8316-8320 C64  
8313 C56  
8314, 8315 C50  
8322 C750  
8330-8332, 8335-8337, 8340-8347, 
8350 
C73  
8370 C740  
8380-8383 C481, C482, C52-C57, C80  
8384 C53  
8390, 8400, 8402-8410, 8413 C300, C44, C51, C60, C632  
8401 C300, C44, C50, C51, C60, C632  
8420 C442  
8440 C07, C08, C25, C481, C482, C54, C56, 
C57, C80 
 
8441, 8460 C481, C482, C54, C56, C57, C80  
8442, 8444, 8450, 8451, 8461-8463, 
8471-8473 
C481, C482, C56, C57  
8452, 8453 C24, C25  
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Table 8. (cont.) 
 
Morphology codes Allowed topography codes Not allowed topography codes 
8470 C181, C25, C56, C57, C80  
8500 C07, C08, C24, C25, C50, C61, C80  
8501-8508, 8512-8514, 8520-8524, 
8530, 8540, 8541, 8543 
C50  
8510 C16, C18, C50, C80  
8525 C003-C005, C01-C08, C300, C31  
8542 C300, C44, C51, C60, C632  
8550, 8551 C003-C005, C01-C08, C25, C30-C34, 
C61, C80 
 
8580-8586 C37  
8588, 8589 C73  
8590-8650 C56, C62  
8670 C56  
8690, 8691 C755  
8692 C754  
8700 C741  
8710, 8711  C420, C421, C77 
8720  C38, C40-C42, C47-C49, C77 
8721-8723, 8730 C21, C300, C44, C51, C60, C632, C69, 
C80 
 
8728 C70  
8740, 8761 C44  
8741, 8743, 8745 C300, C44, C51, C60, C632, C690  
8742 C44, C51, C60, C632  
8744 C446, C447  
8746 C00-C06, C09-C11, C15, C20, C21, C30, 
C31, C680 
 
8770-8772 C300, C44, C51, C60, C632, C690, C80  
8773, 8774 C693, C694  
8780 C44  
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Table 8. (cont.) 
 
Morphology codes Allowed topography codes Not allowed topography codes 
8800-8811, 8814-8831, 8840-8921, 
8963, 8990, 8991, 9040-9043, 9120- 
9150, 9170, 9540, 9550, 9561, 9580, 
9581 
 C420, C421, C77 
8812 C40, C41  
8832, 8833 C44, C51, C60, C632  
8930, 8931 C481, C482, C52-C57  
8933, 8934 C52-C57  
8936 C15-C20, C25, C26, C481, C482, C80  
8940 C003-C005, C04-C08, C300, C44  
8941 C003-C005, C04-C08, C300  
8950, 8951 C481, C482, C52-C57, C80  
8959, 8960, 8964 C64  
8970 C220  
8971 C25  
8972, 8973 C34  
8983 C50  
9000 C56  
9013-9015 C481, C482, C56-C57, C80  
9020 C50  
9044 C49, C80  
9050-9053 C380, C384, C481, C482, C637, C80  
9060 C381-C383, C480, C56, C71, C751, 
C753 
 
9061-9063 C381-C383, C480, C62  
9064, 9065 C381-C383, C480, C495, C56, C62, 
C71, C751, C753, C80 
 
9070-9073, 9080-9085, 9101, 9102 C381-C383, C480, C495, C52-C57, 
C62, C71, C72, C751, C753, C80 
 
9090, 9091 C56  
9100 C381-C383, C480, C56-C58, C62, C80  
9104, 9105 C58  
9124 C220  
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Table 8. (cont.) 
 
Morphology codes Allowed topography codes Not allowed topography codes 
9161 C71-C72  
9180 C40, C41, C480, C49, C50, C80  
9181-9187, 9250 C40, C41  
9192-9195, 9221 C40  
9220, 9230, 9231, 9240-9243 C300, C31, C323, C33, C40, C41, 
C480, C49, C80 
 
9251, 9252 C49  
9260, 9364  C70-C72 
9261 C400, C402  
9270-9342 C03, C310, C410, C411  
9350 C751, C752  
9351, 9352 C752  
9360-9362 C753  
9370-9372 C11, C41, C49  
9380-9384, 9391-9393, 9400-9431, 
9440-9460 
C71, C72, C753  
9390 C715  
9394 C72  
9395 C753  
9432 C751  
9470-9472, 9474, 9480, 9493 C716  
9490, 9500, 9503 C381-C383, C47, C480, C71-C72, 
C741, C755, C80 
 
9492, 9505-9509 C71, C72, C753  
9501, 9502 C694, C71  
9510-9513 C692  
9521-9523 C300, C31, C722  
9530-9539 C70  
9560 C38, C47, C480, C71-C72, C80  
9582 C751  
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Table 8. (cont.) 
 
Morphology codes Allowed topography codes Not allowed topography codes 
9590-9596, 9670-9675, 9680-9688, 
9690-9699, 9702, 9705, 9714, 9724, 
9728, 9729, 9735, 9737, 9738, 
9750-9760, 9762 
 C420, C80 
9597, 9700, 9709, 9718, 9725, 9726 C300, C44, C51, C60, C632  
9650-9667 C024, C09-C11, C14, C220, C421, 
C422, C77 
 
9678 C380, C384, C481, C482  
9679 C379, C381, C383, C771  
9689 C422  
9701 C421, C44, C77  
9708 C44, C49  
9712 C49  
9716 C220, C42  
9717 C16-C18  
9719 C01-C06, C09-C14, C30-C32, C44, 
C696, C77 
 
9727 (BPDCN)* C421, C44  
9731 C40, C41  
9732, 9733, 9742, 9800-9826, 9831- 
9920, 9931-9967, 9975-9989, 9991, 
9992 
C421  
9734  C40, C41, C420, C421, C80 
9741 C220, C42, C44, C77  
9761 C420  
9764 C17  
9827 C421, C77  
9930  C420, C421, C80 
 
* In ICD-O-3, 9727 was used for precursor cell lymphoblastic lymphoma, NOS; in the 2011 updates to ICD-O-3, 9727 is used for blastic 
plasmacytoid dendritic cell neoplasm (BPDCN). The topography codes allowed refer to BPDCN only. 
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3.3. Specific checks for survival analysis 
 
Follow-up time and extent of disease are two 
important components to evaluate and in- 
terpret cancer survival. 
• Consistency of vital status /autopsy, au- 
topsy/basis of diagnosis and autopsy/ 
survival/ dates of incidence and follow-up. 
 
 
Vital status = 1 (alive) Autopsy = 0 (not incidentally diagnosed at autopsy) 
Basis of diagnosis ≠ 0 (DCO) 
Basis of diagnosis = 0 (DCO) Status = 2 (dead) 
Survival (in days) = 0 
Date of incidence = Date of the end of follow-up 
Tumour size/number of examined and metastatic nodes/cTNM/pTNM/ 
condensed TNM/EOD/stage = unknown 
Autopsy = 1 (yes) Status = 2 (dead) 
Survival (in days) = 0 
Date of incidence = Date of the end of follow-up 
 
 
3.4. Other additional checks on the 
extent of the disease 
 
Several variables have been included in or- 
der to retrieve information about the extent 
of disease: tumour size, number of exam- 
ined and metastatic nodes, cTNM, pTNM, 
condensed_TNM, EOD (summary extent 
of disease) and stage grouping. Appendices II 
and III contain detailed TNM6 and TNM7 
stage grouping, respectively, and corre- 
sponding T, N, M values. 
 
Table 1 and Table 2 provide accepted 
values for T, N, M and stage grouping. 
Furthermore, the following additional 
checks are proposed to identify incon-
sistencies among variables related to 
survival: 
•  If C70, C71, C76, C42, C77 and C80, then 
the number of examined and metastatic 
nodes must be ‘99’. 
• If TNM pT = Tis, then ‘basis of diagno- 
sis’ = 7. 
• TNM cT Tis. 
• If site = C80, tumour size = 999.9. 
• If TNM pT TX or 999999, then 
‘basis of diagnosis’ = 7. 
• If TNM pN NX or 99999, then ‘basis 
of diagnosis’ = 5 or 7. 
• If TNM pM MX or 999 then ‘basis 
of diagnosis’ = 5 or 7 or 6. 
• Inconsistencies between topographies and sum- 
mary extent of disease (EOD) 
Topography = C809 and (TNM N = 0, 
TNM M = 0). 
Topography = C809 and (condensed N 
= N0, condensed M = M0). 
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Topography: the fourth digit of the 
topography is = 8 and EOD = 1. 
Topography = C069 and EOD = 1. 
Topography = C26 and EOD = 1. 
Topography = C39 and EOD = 1. 
Topography = C409 and EOD = 1. 
Topography = C419 and EOD = 1. 
Topography = C479 and EOD = 1. 
Topography = C499 and EOD = 1. 
Topography = C559 and EOD = 1. 
Topography = C579 and EOD = 1. 
Topography = C639 and EOD = 1. 
Topography = C809 and EOD = 1. 
Topography = C76 and EOD = 1. 
 
Topography = C77 and TNM N = N0. 
Topography = C77 and condensed N 
= N0. 
• Inconsistencies between behaviour and TNM/ 
EOD 
Behaviour > 2 and pTNM T = Tis. 
Behaviour = 6 and cTNM M = M0. 
Behaviour = 6 and pTNM M = M0. 
Behaviour = 6 and condensed M = 
M0. 
Behaviour = 6 and EOD = 1. 
Behaviour = 6 and EOD = 2 
(excluding nodes). 
• Inconsistencies between EOD = 1 and TNM 
EOD = 1 and TNM N N0. EOD = 
1 and TNM M M0. 
• Inconsistencies  between  EOD  =  1  and  con- 
densed TNM 
EOD = 1 and condensed T TL. 
EOD = 1 and condensed N N0. 
EOD = 1 and condensed M M0. 
• Inconsistencies between EOD = 2 and TNM 
EOD = 2 and TNM M M0. 
EOD = 2 and (pTNM T = Tis or TNM 
T = T1). 
EOD = 2 and TNM N = N0. 
• Inconsistencies between EOD = 2 and con- 
densed TNM 
EOD = 2 and condensed M = M1. 
• Inconsistencies between EOD = 3 and TNM 
EOD = 3 and TNM M = M0. 
• Inconsistencies  between  EOD  =  3  and  con- 
densed TNM 
EOD = 3 and condensed M = M0. 
• Inconsistencies between TNM and 
condensed TNM 
TNM N N0 and condensed N = N0. 
TNM N = N0 and condensed N = N1. 
TNM M = M0 and condensed M = M1. 
TNM M M0 and condensed M = M0. 
• Inconsistencies between N+ and stage 
Number of metastatic nodes > 0 and 
TNM N = N0. 
Number of metastatic nodes > 0 and 
condensed N = N0. 
Number of metastatic nodes > 0 and 
EOD = 1. 
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The quality checklist of warnings for 
Multiple Primary Malignant (MPMTs) 
was developed by the JRC according to 
the current International Rules for 
Multiple Primary Cancers published in 
2004 (http://www.encr.eu/images/docs 
/recommendations/MPrules_july2004.pdf). 
 
This checklist has been addressed by 
the JRC at a later stage than for version 
1.0 of this report, and is therefore 
included in the current version 1.1 to 
clarify the checks and the warning mes -
sages given by the JRC-ENCR Cancer 
Registries Data Quality Check Software. 
 
The steps for checking solid MPMTs 
are the following: 
Step 1. The two topographies are 
compared according to the current 
International Rules for Multiple Malig -
nant Cancers published in 2004.  
In addition to the groups of topog-
raphy codes considered as a single site 
in table 1 of the 2004 international 
rules, for checking other groups are 
considered as a single topography (see 
Table 9).  
C80 (unknown primary site) and C768 
(overlapping lesion of ill-defined sites) are 
considered as a single site with any topog-
raphy.   
 
Table 9. Groups of topography codes considered as a single site for solid tumours 
 
Topography code Definition 
C00 
C03 
C04 
C05 
C06 
C760 
Lip 
Gum 
Floor of mouth 
Palate 
Other and unspecified parts of mouth 
Head, face or neck, NOS 
C01 
C02 
C760 
Base of tongue 
Other and unspecified parts of tongue 
Head, face or neck, NOS 
C07 
C760 
Parotid gland 
Head, face or neck, NOS 
C08 
C760 
Other and unspecified major salivary glands 
Head, face or neck, NOS 
C09 
C10 
C12 
C13 
C14 
C760 
Tonsil 
Oropharynx 
Pyriform sinus 
Hypopharynx 
Other and ill-defined sites in lip, oral cavity and pharynx 
Head, face or neck, NOS 
C11 
C760 
Nasopharynx 
Head, face or neck, NOS 
 
Note: topography codes C80 and C768 are considered as a single site in combination with any other topography.
 
 
Quality Checklist for Multiple 
Primary Malignant Tumours 
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    Table 9. (cont.) 
 
Topography code Definition 
C15 
C268 
C269 
C761 
Oesophagus 
Overlapping lesion of digestive system 
Gastrointestinal tract, NOS 
Thorax, NOS 
C16 
C268 
C269 
C762 
Stomach 
Overlapping lesion of digestive system 
Gastrointestinal tract, NOS 
Abdomen, NOS 
C17 
C26 
C762 
Small intestine 
 Other and ill-defined digestive organs 
Abdomen, NOS 
C18 
C26 
C762 
Colon 
Other and ill-defined digestive organs 
Abdomen, NOS 
C19 
C20 
C26 
C762 
Rectosigmoid junction  
Rectum 
Other and ill-defined digestive organs 
Abdomen, NOS 
C21 
C26 
C76 
Anus and anal canal 
Other and ill-defined digestive organs 
Other and ill-defined sites 
C22 
C268 
C762 
Liver and intrahepatic bile ducts 
Overlapping lesion of digestive system 
Abdomen, NOS 
C23 
C24 
C268 
C269 
C762 
Gallbladder 
Other and unspecified parts of biliary tract 
Overlapping lesion of digestive system 
Gastrointestinal tract, NOS 
Abdomen, NOS 
C25 
C268 
C762 
Pancreas 
Overlapping lesion of digestive system 
Abdomen, NOS 
C30 
C39 
C760 
Nasal cavity and middle ear 
Other and ill-defined sites within respiratory system and intrathoracic organs 
Head, face or neck, NOS 
C31 
C39 
C760 
Accessory sinuses 
Other and ill-defined sites within respiratory system and intrathoracic organs 
Head, face or neck, NOS 
C32 
C39 
C760 
Larynx 
Other and ill-defined sites within respiratory system and intrathoracic organs 
Head, face or neck, NOS 
C33 
C34 
C39 
C760 
C761 
Trachea 
Bronchus and lung 
Other and ill-defined sites within respiratory system and intrathoracic organs 
Head, face or neck, NOS  
Thorax, NOS 
C37 
C761 
Thymus 
Thorax, NOS 
 
Note: topography codes C80 and C768 are considered as a single site in combination with any other topography.
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    Table 9. (cont.) 
 
Topography code Definition 
C38 
C398 
C761 
Heart, mediastinum, and pleura  
Overlapping lesion of respiratory system and intrathoracic organs 
Thorax, NOS 
C39 
C760 
C761 
Other and ill-defined sites within respiratory system and intrathoracic organs 
Head, face or neck, NOS  
Thorax, NOS 
C40 
C41 
C76 
Bones, joints and articular cartilage of limbs 
Bones, joints and articular cartilage of other and unspecified sites 
Other and ill-defined sites 
C44 
C76 
Skin 
Other and ill-defined sites 
C47 
C76 
Peripheral nerves and autonomic nervous system  
Other and ill-defined sites 
C48 
C76 
Retroperitoneum and peritoneum 
Other and ill-defined sites 
C49 
C76 
Connective, subcutaneous and other soft tissues 
Other and ill-defined sites 
C50 
C761 
Breast 
Thorax, NOS 
C51 
C578 
C579 
C763 
Vulva 
Overlapping lesion of female genital organs 
Female genital tract, NOS 
Pelvis, NOS 
C52 
C578 
C579 
C763 
Vagina 
Overlapping lesion of female genital organs 
Female genital tract, NOS 
Pelvis, NOS 
C53 
C55 
C578 
C579 
C763 
Cervix uteri 
Uterus, NOS 
Overlapping lesion of female genital organs 
Female genital tract, NOS 
Pelvis, NOS 
C54 
C55 
C578 
C579 
C763 
Corpus uteri 
Uterus, NOS 
Overlapping lesion of female genital organs 
Female genital tract, NOS 
Pelvis, NOS 
C56 
C578 
C579 
C763 
Ovary 
Overlapping lesion of female genital organs 
Female genital tract, NOS 
Pelvis, NOS 
C57 
C763 
Other and unspecified female genital organs 
Pelvis, NOS 
C58 
C763 
Placenta 
Pelvis, NOS 
C60 
C638 
C639 
C763 
Penis 
Overlapping lesion of male genital organs 
Male genital organs, NOS 
Pelvis, NOS 
 
Note: topography codes C80 and C768 are considered as a single site in combination with any other topography.
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Table 9. (cont.) 
 
Topography code Definition 
C61 
C638 
C639 
C763 
Prostate gland 
Overlapping lesion of male genital organs 
Male genital organs, NOS 
Pelvis, NOS 
C62 
C638 
C639 
C763 
Testis 
Overlapping lesion of male genital organs 
Male genital organs, NOS 
Pelvis, NOS 
C63 
C763 
Other and unspecified male genital organs 
Pelvis, NOS 
C64 
C688 
C689 
C76 
Kidney 
Overlapping lesion of urinary organs 
Urinary system, NOS 
Other and ill-defined sites 
C65  
C66 
C67 
C68 
C76 
Renal pelvis 
Ureter 
Bladder 
Other and unspecified urinary organs 
Other and ill-defined sites 
C69 
C760 
Eye and adnexa 
Head, face or neck, NOS 
C70 
C760 
Meninges 
Head, face or neck, NOS 
C71 
C760 
Brain 
Head, face or neck, NOS 
C72 
C760 
Spinal cord, cranial nerves, and other parts of central nervous system 
Head, face or neck, NOS 
C73 
C760 
Thyroid  
Head, face or neck, NOS 
C74 
C76 
Adrenal gland 
Other and ill-defined sites 
C75 
C76 
Other endocrine glands and related structures 
Other and ill-defined sites 
 
Note: topography codes C80 and C768 are considered as a single site in combination with any other topography.
 
 
a) If the two topographies are in the 
same group, the two morphologies 
are compared (step 2). 
b) If the two topographies are in 
different groups, no warning mes-
sage is given. 
Step 2. The two morphologies are 
compared according to the 2004 Inter-
national Rules.  
Some unspecified morphologies were 
included for checking in the groups 
defined in table 2 of the 2004 International 
Rules, and are considered as the same 
morphology (Table 10). Morphology codes 
8000-8005 (Unspecified types of cancer) are 
considered as a single group in combination 
with any other morphology. 
Note: For haematological malignancies, 
only morphologies are compared. 
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Table 10. Groups of morphology codes considered as a single entity 
 
Morphology code Definition 
8051-8084, 8120-8131  
8010-8015, 8020-8022, 8050  
Squamous and transitional cell carcinoma  
Unspecified carcinomas (NOS)  
8090-8110  
8010-8015, 8020-8022, 8050  
Basal cell carcinomas  
Unspecified carcinomas (NOS)  
8140-8149, 8160-8163, 8190-8221, 8260-8337, 
8350-8552, 8570-8576, 8940-8941  
8010-8015, 8020-8022, 8050  
Adenocarcinomas 
 
Unspecified carcinomas (NOS) 
8030-8046, 8150-8157, 8170-8180, 8230-8255, 
8340-8347, 8560-8562, 8580-8671  
8010-8015, 8020-8022, 8050  
Other specific carcinomas  
 
Unspecified carcinomas (NOS)  
8680-8713, 8800-8921, 8990-8991, 9040-9044, 
9120-9125, 9130-9136, 9141-9252, 9370-9373, 
9540-9582  
Sarcomas and soft tissue tumours  
 
 
9050-9055  Mesothelioma  
9840, 9861-9931, 9945-9946, 9950, 9961-9967, 
9980-9987, 9991-9992  
9590-9591, 9596, 9727, 9760, 9800-9801, 9805-
9809, 9820, 9832, 9835, 9860, 9960, 9970, 9971, 
9975, 9989  
Myeloid  
 
Unspecified types of haematopoietic and lymphoid tissues  
 
 
9597, 9670-9699, 9712, 9728, 9731-9738, 9761-
9767, 9769, 9811-9818, 9823, 9826, 9833, 9836, 
9940  
9590-9591, 9596, 9727, 9760, 9800-9801, 9805-
9809, 9820, 9832, 9835, 9860, 9960, 9970, 9971, 
9975, 9989  
B–cell neoplasms  
 
 
Unspecified types of haematopoietic and lymphoid tissues  
 
 
9700-9709, 9714-9719, 9724-9726, 9729, 9768, 
9827, 9831, 9834, 9837, 9948  
9590-9591, 9596, 9727, 9760, 9800-9801, 9805-
9809, 9820, 9832, 9835, 9860, 9960, 9970, 9971, 
9975, 9989  
T–cell and NK–cell neoplasms  
 
Unspecified types of haematopoietic and lymphoid tissues  
 
 
9650-9667  
9590-9591, 9596, 9727, 9760, 9800-9801, 9805-
9809, 9820, 9832, 9835, 9860, 9960, 9970, 9971, 
9975, 9989  
Hodgkin lymphoma  
Unspecified types of haematopoietic and lymphoid tissues  
 
 
9740-9742  
9590-9591, 9596, 9727, 9760, 9800-9801, 9805-
9809, 9820, 9832, 9835, 9860, 9960, 9970, 9971, 
9975, 9989  
Mast–cell tumours  
Unspecified types of haematopoietic and lymphoid tissues  
 
 
9750-9759  
9590-9591, 9596, 9727, 9760, 9800-9801, 9805-
9809, 9820, 9832, 9835, 9860, 9960, 9970, 9971, 
9975, 9989 
Histiocytes and Accessory Lymphoid cells  
Unspecified types of haematopoietic and lymphoid tissues 
9140 Kaposi sarcoma 
8720-8790, 8930-8936, 8950-8983, 9000-9030, 
9060-9110, 9260-9365, 9380-9539 
Other specified types of cancer 
 
Note: morphology codes 8000-8005 (unspecified types of cancer) are considered as a single group in combination with any other 
morphology.
   5. References    |   47 
 
 
References
Allemani C, Weir HK, Carreira H et al. and 
the CONCORD Working Group. Global 
surveillance of cancer survival 1995-
2009:   analysis   of   individual  data   for  
25 676 887 patients from 279 population- 
based registries in 67 countries (CON-
CORD-2). Lancet, 2015, 385(9972):977-
1010. 
Anatomical Therapeutic Chemical (ATC) classi- 
fication system. WHO Collaborating Cen-
tre for Drug Statistics. Available in 
http://www.whocc.no/atc_ddd_index/. 
Bray F, Parkin DM. Evaluation of data qual- 
ity in the cancer registry: Principles and 
methods. Part I: Comparability, validity 
and timeliness. Eur J Cancer, 2009, 45: 747 - 
755. 
De Angelis R, Francisci S, Baili P  et al. The 
EUROCARE-4 database on cancer 
survival in Europe: Data standardisation, 
quality control and methods of statistical 
analysis. Eur J Cancer, 2009, 45: 909- 930. 
ENCR Recommendations. Available in http:// 
www.encr.eu/working-groups-and-recom 
mendations. 
EUROCARE. Checking   procedures   of   the 
EUROCARE-4 Data Base. Available in 
http://www.eurocare.it/Eurocare4DataC
hecking/tabid/81/Default.aspx. 
Ferlay J, Burkhard C, Whelan S, Parkin 
DM. Check and conversion programs for 
cancer registries (IARC /IACR tools for 
cancer registries). International Agency 
for Research on Cancer/International 
Association of Cancer Registries, IARC 
Technical Report No. 42, Lyon, 2005. 
Ferretti S, Giacomin A and Airtum 
Working Group. Cancer registration hand-
book. Available in http://www.registri-
tumori.it/cms/pubblicazioni/cancer-
registration-handbook-2010. 
North American Association of 
Central Cancer Registries. NAACCR 
V14 Metafile Edit Detail Report– 
November 26, 2013.   Available in 
http://www.naaccr.org/wp-content/ 
uploads/2016/11/NAACCR-v14-Beta-
Edits-Detail-Report.pdf. 
Parkin DM, Bray F. Evaluation of data 
quality in the cancer registry: Princi-
ples and methods. Part II: Complete-
ness. Eur J Cancer, 2009, 45: 756- 764. 
Percy C, Fritz A, Jack A, 
Shanmugarathan S, Sobin L, Parkin 
DM, Whelan S. International Classifica-
tion of Diseases for Oncology (ICD-O). 
World Health Organization, 3rd ed., 
December 2000. 
Sobin LH, Gospodarowicz MK, 
Wittekind Ch, eds. TNM Classification 
of Malignant Tumors. 7th ed., Wiley-
Blackwell, Oxford, 2009. 
Sobin LH, Wittekind Ch. TNM Classifi-
cation  of  Malignant  Tumours. 6 th ed., John 
Wiley & Sons, Hoboken, New Jersey, 
2002.  
TNM Classification Help. Manual for Cancer 
Staging. Available in cancerstaging.  
blogspot.com
48   |   A proposal on cancer data quality checks: one common procedure for European cancer registries 
 
 
Appendix I: The Anatomical Therapeutic Chemical 
(ATC) code, generic and trade names 
 
Chemotherapy 
 
ATC code Generic name Trade name 
L01XX32 Bortezomib VELCADE 
L01XX17 Topotecan HYCAMTIN 
TOPOTECAN 
L01XX19 Irinotecan IRINOTECAN HYDROCH 
CAMPTO 
IRINOTECAN ACTAVIS 
L01XX05 Hydroxycarbamide HYDREA 
L01XX14 Tretinoin VESANOID 
L01XX02 Asparaginase KIDROLASE 
L01XX11 Estramustine ESTRACYT 
L01XA03 Oxaliplatin ELOXATIN 
OXALIPLATINE ACTAV 
OXALIPLATINE 
L01XA02 Carboplatin CARBOPLATIN 
PARAPLATIN 
L01XA01 Cisplatin SINPLATIN 
CISPLATIN 
PLATIDIAM 
PLATINEX 
L01BC06 Capecitabine XELODA 
L01BC05 Gemcitabine GEMZAR 
L01BC02 Fluorouracil FLUOROURACIL ACCOR 
FLUOROURACIL 5 
5-FU 
FLUOROURACIL 
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Chemotherapy (cont.) 
 
ATC code Generic name Trade name 
L01BC01 Cytarabine ALEXAN 
CYTARABINE 
CYTOSAR 
L01BC53 Tegafur combinations UFT 
L01BA04 Pemetrexed ALIMTA 
L01BA01 Methotrexate METHOTREXATE 
L01BA03 Raltitrexed TOMUDEX 
L01BB05 Fludarabine FLUDARA 
L01BB02 Mercaptopurine PURI NETHOL 
L01BB07 Nelarabine ATRIANCE 
L01BB04 Cladribine LITAK 10 
L01BB03 Tioguanine LANVIS 
L01CD02 Docetaxel TAXOTERE 
DOCETAX 
L01CD01 Paclitaxel SINDAXEL 
PACLITAXEL 
TAXOL 
GENEXOL 
PACLITEVA 
PACLITAXIN 
L01CA04 Vinorelbine VINORELBIN ACTAVIS 
NAVELBIN 
VINORELBIN EBEWE 
L01CA02 Vincristine CYTOCRISTIN 
VINCRISTIN 
L01CA01 Vinblastine CYTOBLASTIN 
VINBLASTIN 
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Chemotherapy (cont.) 
 
ATC code Generic name Trade name 
L01CB01 Etoposide ETOSID 
ETOPOSIDE 
LASTET 
VEPESID 
L01CB02 Teniposide VUMON 
L01CX01 Trabectedin YONDELIS 
L01AX03 Temozolomide TEMODAL 
L01AX04 Dacarbazine DACARBAZIN 
L01AA06 Ifosfamide HOLOXAN 
L01AA01 Cyclophosphamide ENDOXAN 
L01AA03 Melphalan ALKERAN 
L01AA02 Chlorambucil LEUKERAN 
L01AD01 Carmustine BCNU 
L01AD02 Lomustine CCUN 
L01AB01 Busulfan MYLERAN 
L01DB03 Epirubicin FARMORUBICIN 
EPIRUBICIN 
EPILEM 
EPISINDAN 
L01DB06 Idarubicin ZAVEDOS 
L01DB07 Mitoxantrone MITOXANTRON 
ONCOTRONE 
NOVANTRONE 
L01DB01 Doxorubicin DOXORUBICIN 
CAELYX 
L01DC03 Mitomycin MITOMYCIN C 
L01DC01 Bleomycin BLEOCIN 
L01DA01 Dactinomycin COSMEGEN LYOVAC 
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Hormonal therapy 
 
ATC code Generic name Trade name 
L02BG04 Letrozole FEMARA 
LETROZOL NUCLEUS 
L02BG03 Anastrozole ARIMIDEX 
ANAROMAT 
L02BG06 Exemestane AROMASIN 
L02BG01 Aminogluthetimide AMINOGLUTETHIMID 
ORIMETEN 
L02BA03 Fulvestrant FASLODEX 
L02BA01 Tamoxifen NOLVADEX 
TAMOXIFEN 
TAMIFEN 
L02BB03 Bicalutamide BICUSAN 
CASODEX 
L02BB01 Flutamide FLUTASIN 
FLUCINOM 
FLUTAMIDE 
L02AE03 Goserelin ZOLADEX 
L02AE02 Leuprorelin LUCRIN DEPOT 
ELIGARD 
L02AE01 Buserelin SUPREFACT 
L02AE04 Triptorelin DECAPEPTYL 
DIPHERELINE 
DIPHERELINE SR 
L02AB01 Megestrol MEGACE 
L02AB02 Medroxyprogesterone MEDROXYPROGESTERON 
MPA 
G03HA01 Cyproterone ANDROCUR 
G03DA02 Medroxyprogesterone FARLUTAL 
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Systemic therapies other than chemotherapy and hormonal therapy 
 
Targeted therapy 
ATC code Generic name Trade name 
L01XC03 Trastuzumab HERCEPTIN 
L01XC02 Rituximab MABTHERA 
L01XC07 Bevacizumab AVASTIN 
L01XC06 Cetuximab ERBITUX 
L01XC08 Panitumumab VECTIBIX 
L01XC04 Alemtuzumab MABCAMPATH 
L01XE01 Imatinib GLIVEC 
L01XE04 Sunitinib SUTENT 
L01XE03 Erlotinib TARCEVA 
L01XE05 Sorafenib NEXAVAR 
L01XE07 Lapatinib TYVERB 
L01XE06 Dasatinib SPRYCEL 
L01XE08 Nilotinib TASIGNA 
 
Immunotherapy 
ATC code Generic name Trade name 
L03AA13 Pegfilgrastim NEULASTA 
L03AA02 Filgrastim NEUPOGEN 
TEVAGRASTIM 
L03AA10 Lenograstim GRANOCYTE 
L03AB01 Interferon alfa natural ROFERON A 
L03AB05 Interferon alfa-2b REALDIRON 
INTRON A 
 
Other therapies 
ATC code Generic name Trade name 
A04AA01 Ondansetron ZOFRAN 
ZONDARON 
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Systemic therapies other than chemotherapy and hormonal therapy (cont.) 
 
Other therapies (cont.) 
ATC code Generic name Trade name 
A04AA02 Granisetron KYTRIL 
RASETRON 
A04AA04 Dolasetron ANZEMET 
A04AA05 Palonosetron ALOXI 
A04AA03 Tropisetron NAVOBAN 
B03XA01 Erythropoietin NEO RECORMON 
EPREX 
B03XA03 Pegzerepoetinalfa MIRCERA 
B03XA02 Darbepoetinalfa ARANESP 
M05BA08 Zoledronic acid ZOMETA 
M05BA06 Ibandronic acid BONDRONAT 
M05BA03 Pamidronic acid PAMITOR 
AREDIA 
M05BA02 Clodronic acid SINDRONAT 
BONEFOS 
OSTAC 
H02AB07 Prednisone DEHYDROCORTISON 
H02AB06 Prednisolone PREDNISOLON CORTIC 
PREDNISOLON 
H02AB02 Dexamethasone DEXAMETHASONE 
DEXAVEN 
PREDNISOLON F 
H02AB04 Methylprednisolone METHYLPREDN.SOPHAR 
SOLU MEDROL 
DEPO MEDROL 
MEDROL 
METHYLPREDN.CORTIC 
METHYLPREDNISOLON 
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Appendix II: TNM 6 edition stage grouping 
and corresponding T, N, M values 
 
 
Lip and Oral Cavity C00, C02-C06 (except C051 and C052) 
Stage Т N M 
0 Tis N0 M0 
I T1 N0 M0 
II T2 N0 M0 
III T1, T2 N1 M0 
T3 N0, N1 M0 
IVA T1, T2, T3 N2 M0 
T4a N0, N1, N2 M0 
IVB Any T N3 M0 
T4b Any N M0 
IVC Any T Any N M1 
 
Oropharynx and Hypopharynx C01, C051, C052, C090, C091, C099, C100, C102, C103, C12, C13 
Stage Т N M 
0 Tis N0 M0 
I T1 N0 M0 
II T2 N0 M0 
III T1, T2 N1 M0 
T3 N0, N1 M0 
IVA T1, T2, T3 N2 M0 
T4a N0, N1, N2 M0 
IVB T4b Any N M0 
Any T N3 M0 
IVC Any T Any N M1 
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Nasopharynx С11 
Stage Т N M 
0 Tis N0 M0 
I T1 N0 M0 
IIA T2a N0 M0 
IIB T1 N1 M0 
T2a N1 M0 
T2b N0, N1 M0 
III T1 N2 M0 
T2a, T2b N2 M0 
T3 N0, N1, N2 M0 
IVA T4 N0, N1, N2 M0 
IVB Any T N3 M0 
IVC Any T Any N M1 
 
 
Larynx C320, C321, C322, C101 
Stage Т N M 
0 Tis N0 M0 
I T1 N0 M0 
II T2 N0 M0 
III T1, T2 N1 M0 
T3 N0, N1 M0 
IVA T1, T2, T3 N2 M0 
T4a N0, N1, N2 M0 
IVB T4b Any N M0 
Any T N3 M0 
IVC Any T Any N M1 
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Nasal Cavity and Paranasal Sinuses C300, C310, C311 
Stage Т N M 
0 Tis N0 M0 
I T1 N0 M0 
II T2 N0 M0 
III T1, T2 N1 M0 
T3 N0, N1 M0 
IVA T1, T2, T3 N2 M0 
T4a N0, N1, N2 M0 
IVB T4b Any N M0 
Any T N3 M0 
IVC Any T Any N M1 
 
 
Salivary Glands C07, C08 
Stage Т N M 
I T1 N0 M0 
II T2 N0 M0 
III T3 N0 M0 
T1, T2, T3 N1 M0 
IVA T1, T2, T3 N2 M0 
T4a N0, N1, N2 M0 
IVB T4b Any N M0 
Any T N3 M0 
IVC Any T Any N M1 
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Thyroid Gland C73 
Stage Т N M 
Papillary or Follicular, under 45 years 
I Any T Any N M0 
II Any T Any N M1 
Papillary or Follicular, 45 years and older, and Medullary 
I T1 N0 M0 
II T2 N0 M0 
III T3 N0 M0 
T1, T2, T3 N1a M0 
IVA T1, T2, T3 N1b M0 
T4a N0, N1 M0 
IVB T4b Any N M0 
IVC Any T Any N M1 
Anaplastic/ Undifferentiated (all cases are stage IV) 
IVA T4a Any N M0 
IVB T4b Any N M0 
IVC Any T Any N M1 
 
 
Oesophagus C15 
Stage Т N M 
0 Tis N0 M0 
I T1 N0 M0 
IIA T2, T3 N0 M0 
IIB T1, T2 N1 M0 
III T3 N1 M0 
T4 Any N M0 
IV Any T Any N M1 
IVA Any T Any N M1a 
IVB Any T Any N M1b 
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Stomach С16 
Stage Т N M 
0 Tis N0 M0 
IA T1 N0 M0 
IB T1 N1 M0 
T2a/ b N0 M0 
II T1 N2 M0 
T2a/ b N1 M0 
T3 N0 M0 
IIIA T2a/ b N2 M0 
T3 N1 M0 
T4 N0 M0 
IIIB T3 N2 M0 
IV T4 N1, N2, N3 M0 
T1, T2, T3 N3 M0 
Any T Any N M1 
 
 
Small Intestine С17 
Stage Т N M 
0 Tis N0 M0 
I T1, T2 N0 M0 
II T3, T4 N0 M0 
III Any T N1 M0 
IV Any T Any N M1 
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Colon and Rectum С18-С20 
Stage Т N M 
0 Tis N0 M0 
I T1, T2 N0 M0 
IIA T3 N0 M0 
IIB T4 N0 M0 
IIIA T1, T2 N1 M0 
IIIB T3, T4 N1 M0 
IIIC Any T N2 M0 
IV Any T Any N M1 
 
 
Anal Canal С211 
Stage Т N M 
0 Tis N0 M0 
I T1 N0 M0 
II T2 N0 M0 
T3 N0 M0 
IIIA T1, T2, T3 N1 M0 
T4 N0 M0 
IIIB T4 N1 M0 
Any T N2, N3 M0 
IV Any T Any N M1 
 
 
Liver С220, C221 
Stage Т N M 
I T1 N0 M0 
II T2 N0 M0 
IIIA T3 N0 M0 
IIIB T4 N0 M0 
IIIC Any T N1 M0 
IV Any T Any N M1 
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Gallbladder С23 
Stage Т N M 
0 Tis N0 M0 
IA T1 N0 M0 
IB T2 N0 M0 
IIA T3 N0 M0 
IIB T1, T2, T3 N1 M0 
III T4 Any N M0 
IV Any T Any N M1 
 
 
Extrahepatic Bile Ducts С240 
Stage Т N M 
0 Tis N0 M0 
IA T1 N0 M0 
IB T2 N0 M0 
IIA T3 N0 M0 
IIB T1, T2, T3 N1 M0 
III T4 Any N M0 
IV Any T Any N M1 
 
 
Ampulla of Vater С241 
Stage Т N M 
0 Tis N0 M0 
IA T1 N0 M0 
IB T2 N0 M0 
IIA T3 N0 M0 
IIB T1, T2, T3 N1 M0 
III T4 Any N M0 
IV Any T Any N M1 
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Pancreas С25 
Stage Т N M 
0 Tis N0 M0 
IA T1 N0 M0 
IB T2 N0 M0 
IIA T3 N0 M0 
IIB T1, T2, T3 N1 M0 
III T4 Any N M0 
IV Any T Any N M1 
 
 
Lung С34 
Stage Т N M 
Occult carcinoma TХ N0 M0 
0 Tis N0 M0 
IA T1 N0 M0 
IB T2 N0 M0 
IIA T1 N1 M0 
IIB T2 N1 M0 
T3 N0 M0 
IIIA T1, T2 N2 M0 
T3 N1, N2 M0 
IIIB Any T N3 M0 
T4 Any N M0 
IV Any T Any N M1 
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Pleural Mesothelioma С384 
Stage Т N M 
IA T1a N0 M0 
IB T1b N0 M0 
II T2 N0 M0 
III T1, T2 N1 M0 
T1, T2 N2 M0 
T3 N0, N1, N2 M0 
IV T4 Any N M0 
Any T N3 M0 
Any T Any N M1 
 
 
Bone С40, С41 
Stage Т N M Grade (G) 
IA T1 N0, NХ M0 1, 2 
IB T2 N0, NХ M0 1, 2 
IIA T1 N0, NХ M0 3, 4 
IIB T2 N0, NХ M0 3, 4 
III T3 N0, NХ M0 Any G 
IVA Any T N0, NХ M1a Any G 
IVB Any T N1 Any M Any G 
Any T Any N M1b Any G 
Appendix II :  TNM 6 edition stage grouping and corresponding T, N, M values    |   63 
 
 
 
Soft Tissues С381, C382,C383, С47-С49 
Stage Т N M Grade (G) 
IA T1а N0, NХ M0 1, 2 
T1b N0, NХ M0 1, 2 
IB T2a N0, NХ M0 1, 2 
T2b N0, NХ M0 1, 2 
IIA T1a N0, NХ M0 3, 4 
T1b N0, NХ M0 3, 4 
IIB T2a N0, NХ M0 3, 4 
III T2b N0, NХ M0 3, 4 
IV Any T N1 M0 Any G 
Any T Any N M1 Any G 
 
 
Carcinoma of Skin (excluding eyelid, vulva, and penis) С440, C442-C449, С632 
Stage Т N M 
0 Tis N0 M0 
I T1 N0 M0 
II T2, T3 N0 M0 
III T4 N0 M0 
Any T N1 M0 
IV Any T Any N M1 
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Malignant Melanoma of Skin C44, C510, C609, C632 
Stage Т N M 
0 pTis N0 M0 
I pT1 N0 M0 
IA pT1a N0 M0 
IB pT1b N0 M0 
pT2a N0 M0 
IIA pT2b N0 M0 
pT3a N0 M0 
IIB pT3b N0 M0 
pT4a N0 M0 
IIC pT4b N0 M0 
III Any pT N1, N2, N3 M0 
IIIA pT1a-pT4a N1a, N2a M0 
IIIB pT1a-pT4a N1b, N2b, N2c M0 
pT1b-pT4b N1a, N2a, N2c M0 
IIIC pT1b-pT4b N1b, N2b M0 
Any pT N3 M0 
IV Any pT Any N M1 
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Breast Tumours С50 
Stage Т N M 
0 Tis N0 M0 
I T1 N0 M0 
IIA T0 N1 M0 
T1 N1 M0 
T2 N0 M0 
IIB T2 N1 M0 
T3 N0 M0 
IIIA T0 N2 M0 
T1 N2 M0 
T2 N2 M0 
T3 N1, N2 M0 
IIIB T4 N0, N1, N2 M0 
IIIC Any T N3 M0 
IV Any T Any N M1 
 
 
Vulva С51 
Stage Т N M 
0 Tis N0 M0 
I T1 N0 M0 
IA T1а N0 M0 
IB T1b N0 M0 
II T2 N0 M0 
III T1, T2 N1 M0 
T3 N0, N1 M0 
IVA T1, T2, T3 N2 M0 
T4 Any N M0 
IVB Any T Any N M1 
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Vagina С52 
Stage Т N M 
0 Tis N0 M0 
I T1 N0 M0 
II T2 N0 M0 
III T3 N0 M0 
T1, T2, T3 N1 M0 
IVA T4 Any N M0 
IVB Any T Any N M1 
 
 
Cervix Uteri С53 
Stage Т N M 
0 Tis N0 M0 
IA T1a N0 M0 
IA1 T1a1 N0 M0 
IA2 T1a2 N0 M0 
IB T1b N0 M0 
IB1 T1b1 N0 M0 
IB2 T1b2 N0 M0 
IIA T2a N0 M0 
IIB T2b N0 M0 
IIIA T3a N0 M0 
IIIB T1, T2, T3a N1 M0 
T3b Any N M0 
IVA T4 Any N M0 
IVB Any T Any N M1 
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Corpus Uteri С54 
Stage Т N M 
0 Tis N0 M0 
IA T1a N0 M0 
IB T1b N0 M0 
IC T1c N0 M0 
IIA T2a N0 M0 
IIB T2b N0 M0 
IIIA T3a N0 M0 
IIIB T3b N0 M0 
IIIC T1, T2, T3 N1 M0 
IVA T4 Any N M0 
IVB Any T Any N M1 
 
 
Ovary С56 
Stage Т N M 
IA T1a N0 M0 
IB T1b N0 M0 
IC T1c N0 M0 
IIA T2a N0 M0 
IIB T2b N0 M0 
IIC T2c N0 M0 
IIIA T3a N0 M0 
IIIB T3b N0 M0 
IIIC T3c N0 M0 
Any T N1 M0 
IV Any T Any N M1 
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Fallopian Tube С570 
Stage Т N M 
0 Tis N0 M0 
IA T1a N0 M0 
IB T1b N0 M0 
IC T1c N0 M0 
IIA T2а N0 M0 
IIB T2b N0 M0 
IIC T2c N0 M0 
IIIA T3a N0 M0 
IIIB T3b N0 M0 
IIIC T3c N0 M0 
Any T N1 M0 
IV Any T Any N M1 
 
 
Gestational Trophoblastic Tumours С58 
Stage Т N – not applicable M Risk category 
I T1  M0 unknown 
IA T1  M0 low 
IB T1  M0 high 
II T2  M0 unknown 
IIA T2  M0 low 
IIB T2  M0 high 
III Any T  M1a unknown 
IIIA Any T  M1a low 
IIIB Any T  M1a high 
IV Any T  M1b unknown 
IVA Any T  M1b low 
IVB Any T  M1b high 
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Penis С60 
Stage Т N M 
0 Tis N0 M0 
Tа N0 M0 
I T1 N0 M0 
II T1 N1 M0 
T2 N0 M0 
T2 N1 M0 
III T1, T2 N2 M0 
T3 N0, N1, N2 M0 
IV T4 Any N M0 
Any T N3 M0 
Any T Any N M1 
 
 
Prostate С61 
Stage Т N M Grade (G) 
I T1a N0 M0 1 
II T1a N0 M0 2, 3, 4 
T1b, T1c N0 M0 Any G 
T1, T2 N0 M0 Any G 
III T3 N0 M0 Any G 
IV T4 N0 M0 Any G 
Any T N1 M0 Any G 
Any T Any N M1 Any G 
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Теstis С62 
Stage Т N M Serum tumour markers 
0 pTis N0 M0 S0, SX 
I pT1-T4 N0 M0 SX 
IA pT1 N0 M0 S0 
IB pT2 N0 M0 S0 
pT3 N0 M0 S0 
pT4 N0 M0 S0 
IS Any pT, Tx N0 M0 S1-S3 
II Any pT, Tx N1-N3 M0 SX 
IIA Any pT, Tx N1 M0 S0 
Any pT, Tx N1 M0 S1 
IIB Any pT, Tx N2 M0 S0 
Any pT, Tx N2 M0 S1 
IIC Any pT, Tx N3 M0 S0 
Any pT, Tx N3 M0 S1 
III Any pT, Tx Any N M1, M1a SX 
IIIA Any pT, Tx Any N M1, M1a S0 
Any pT, Tx Any N M1, M1a S1 
IIIB Any pT, Tx N1-N3 M0 S2 
Any pT, Tx Any N M1, M1a S2 
IIIC Any pT, Tx N1-N3 M0 S3 
Any pT, Tx Any N M1, M1a S3 
Any pT, Tx Any N M1b Any S 
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Kidney С64 
Stage Т N M 
I T1 N0 M0 
II T2 N0 M0 
III T3 N0 M0 
T1, T2, T3 N1 M0 
IV T4 N0, N1 M0 
Any T N2 M0 
Any T Any N M1 
 
 
Renal Pelvis and Ureter С65, С66 
Stage Т N M 
0a Ta N0 M0 
0is Tis N0 M0 
I T1 N0 M0 
II T2 N0 M0 
III T3 N0 M0 
IV T4 N0 M0 
Any T N1, N2, N3 M0 
Any T Any N M1 
 
 
Urinary Bladder С67 
Stage Т N M 
0a Ta N0 M0 
0is Tis N0 M0 
I T1 N0 M0 
II T2a, b N0 M0 
III T3a, b N0 M0 
T4a N0 M0 
IV T4b N0 M0 
Any T N1, N2, N3 M0 
Any T Any N M1 
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Urethra С680 
Stage Т N M 
0a Ta N0 M0 
0is Tis N0 M0 
Tispu N0 M0 
Tispd N0 M0 
I T1 N0 M0 
II T2 N0 M0 
III T1, T2 N1 M0 
T3 N0, N1 M0 
IV T4 N0, N1 M0 
Any T N2 M0 
Any T Any N M1 
 
 
Malignant Melanoma of Uvea С693, C694 
Stage Т N M 
I T1 N0 M0 
II T2 N0 M0 
III T3, T4 N0 M0 
IV Any T N1 M0 
Any T Any N M1 
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Appendix III: TNM 7 edition stage grouping 
and corresponding T, N, M values 
 
 
Lip and Oral Cavity C00, C02-C06 (except C051 and C052) 
Stage Т N M 
0 Tis N0 M0 
I T1 N0 M0 
II T2 N0 M0 
III T1, T2, T3 N1 M0 
T3 N0 M0 
IVA T1, T2, T3, T4a N2 M0 
T4a N0, N1 M0 
IVB Any T N3 M0 
T4b Any N M0 
IVC Any T Any N M1 
 
Oropharynx and Hypopharynx C01, C051, C052, C09, C100, C102, C103, C12, C13 
Stage Т N M 
0 Tis N0 M0 
I T1 N0 M0 
II T2 N0 M0 
III T1, T2, T3 N1 M0 
T3 N0 M0 
IVA T1, T2, T3 N2 M0 
T4a N0, N1, N2 M0 
IVB T4b Any N M0 
Any T N3 M0 
IVC Any T Any N M1 
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Nasopharynx С11 
Stage Т N M 
0 Tis N0 M0 
I T1 N0 M0 
II T2 N0, N1 M0 
T1 N1 M0 
III T1, T2 N2 M0 
T3 N0, N1, N2 M0 
IVA T4 N0, N1, N2 M0 
IVB Any T N3 M0 
IVC Any T Any N M1 
 
 
Larynx C320, C321, C322, C101 
Stage Т N M 
0 Tis N0 M0 
I T1 N0 M0 
II T2 N0 M0 
III T1, T2 N1 M0 
T3 N0, N1 M0 
IVA T1, T2, T3 N2 M0 
T4a, T4b N0, N1 M0 
IVB T4b Any N M0 
Any T N3 M0 
IVC Any T Any N M1 
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Nasal Cavity and Paranasal Sinuses C300, C310, C311 
Stage Т N M 
0 Tis N0 M0 
I T1 N0 M0 
II T2 N0 M0 
III T1, T2, T3 N1 M0 
T3 N0 M0 
IVA T1, T2, T3 N2 M0 
T4a N0, N1, N2 M0 
IVB T4b Any N M0 
Any T N3 M0 
IVC Any T Any N M1 
 
 
Malignant Melanoma of Upper Aerodigestive Tract C00-C06, C10-C14, C30-C32 
Stage Т N M 
III T3 N0 M0 
IVA T3, T4a N1 M0 
T4a N0 M0 
IVB T4b Any N M0 
IVC Any T Any N M1 
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Major Salivary Glands C07, C08 
Stage Т N M 
I T1 N0 M0 
II T2 N0 M0 
III T3 N0 M0 
T1, T2, T3 N1 M0 
IVA T4a N0 M0 
T4a N1 M0 
T1, T2, T3, T4a N2 M0 
IVB T4b Any N M0 
Any T N3 M0 
IVC Any T Any N M1 
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Thyroid Gland C73 
Stage Т N M 
Papillary or Follicular, under 45 years 
I Any T Any N M0 
II Any T Any N M1 
Papillary or Follicular, 45 years and older 
I T1a, T1b N0 M0 
II T2 N0 M0 
III T3 N0 M0 
T1, T2, T3 N1a M0 
IVA T1, T2, T3 N1b M0 
T4a N0, N1 M0 
IVB T4b Any N M0 
IVC Any T Any N M1 
Medullary 
I T1a, T1b N0 M0 
II T2, T3 N0 M0 
III T1, T2, T3 N1a M0 
IVA T1, T2, T3 N1b M0 
T4a Any N M0 
IVB T4b Any N M0 
IVC Any T Any N M1 
Anaplastic/ Undifferentiated (all cases are stage IV) 
IVA T4a Any N M0 
IVB T4b Any N M0 
IVC Any T Any N M1 
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Oesophagus C15, C160 
Stage Т N M 
0 Tis N0 M0 
IA T1 N0 M0 
IB T2 N0 M0 
IIA T3 N0 M0 
IIB T1, T2 N1 M0 
IIIA T4a N0 M0 
T3 N1 M0 
T1, T2 N2 M0 
IIIB T3 N2 M0 
IIIC T4a N1, N2 M0 
T4b Any N M0 
Any T N3 M0 
IV Any T Any N M1 
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Stomach С161-C164 
Stage Т N M 
0 Tis N0 M0 
IA T1 N0 M0 
IB T2 N0 M0 
T1 N1 M0 
IIA T3 N0 M0 
T2 N1 M0 
T1 N2 M0 
IIB T4a N0 M0 
T3 N1 M0 
T2 N2 M0 
T1 N3 M0 
IIIA T4a N1 M0 
T3 N2 M0 
T2 N3 M0 
IIIB T4b N0, N1 M0 
T4a N2 M0 
T3 N3 M0 
IIIC T4a N3 M0 
T4b N2, N3 M0 
IV Any T Any N M1 
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Small Intestine С17 
Stage Т N M 
0 Tis N0 M0 
I T1, T2 N0 M0 
IIA T3 N0 M0 
IIB T4 N0 M0 
IIIA Any T N1 M0 
IIIB Any T N2 M0 
IV Any T Any N M1 
 
 
Appendix-Carcinoma С181 
Stage Т N M Grade (G) 
0 Tis N0 M0  
I T1, T2 N0 M0  
IIA T3 N0 M0  
IIB T4a N0 M0  
IIC T4b N0 M0  
IIIA T1, T2 N1 M0  
IIIB T3, T4 N1 M0  
IIIC Any T N2 M0  
IVA Any T N0 M1a G1 
IVB Any T N0 M1a G2, G3 
Any T N1, N2 M1a Any G 
IVC Any T Any N M1b Any G 
 
Note: G1 well-differentiated/ mucinous low grade; G2 moderately differentiated/ mucinous high grade; G3 poorly differentiated/ muci- 
nous high grade; G4 undifferentiated. 
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Appendix-Carcinoid (Well-differentiated neuroendocrine tumour) 
Stage Т N M 
I T1 N0 M0 
II T2, T3 N0 M0 
III T4 N0 M0 
Any T N1 M0 
IV Any T Any N M1 
 
 
Colon and Rectum С18-С20, excluded C181 
Stage Т N M 
0 Tis N0 M0 
I T1, T2 N0 M0 
II T3, T4 N0 M0 
IIA T3 N0 M0 
IIB T4a N0 M0 
IIC T4b N0 M0 
III Any T N1, N2 M0 
IIIA T1, T2 N1 M0 
T1 N2a M0 
IIIB T3, T4a N1 M0 
T2, T3 N2a M0 
T1, T2 N2b M0 
IIIC T4a N2a M0 
T3, T4a N2b M0 
T4b N1, N2 M0 
IVA Any T Any N M1a 
IVB Any T Any N M1b 
82   |   A proposal on cancer data quality checks: one common procedure for European cancer registries 
 
 
 
Anal Canal С211 
Stage Т N M 
0 Tis N0 M0 
I T1 N0 M0 
II T2, T3 N0 M0 
IIIA T1, T2, T3 N1 M0 
T4 N0 M0 
IIIB T4 N1 M0 
Any T N2, N3 M0 
IV Any T Any N M1 
 
 
Gastrointestinal Stromal Tumour (GIST) 
Stage Т N M Mitotic rate 
Gastric GIST* 
IA T1, T2 N0 M0 Low 
IB T3 N0 M0 Low 
II T1, T2 N0 M0 High 
T4 N0 M0 Low 
IIIA T3 N0 M0 High 
IIIB T4 N0 M0 High 
IV Any T N1 M0 Any rate 
Any T Any N M1 Any rate 
Small Intestinal GIST* 
I T1, T2 N0 M0 Low 
II T3 N0 M0 Low 
IIIA T1 N0 M0 High 
T4 N0 M0 Low 
IIIB T2, T3, T4 N0 M0 High 
IV Any T N1 M0 Any rate 
Any T Any N M1 Any rate 
 
*  Staging criteria for gastric tumours can be applied in primary, solitary omental GISTs. Staging criteria for intestinal tumours can be 
applied to GISTs in less common sites, such as oesophagus, colon, rectum and mesentery. 
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Gastric, Small, and Large Intestinal Carcinoid Tumours 
(Well-differentiated Neuroendocrine Tumours and Well-differentiated Neuroendocrine Carcinomas) 
Stage Т N M 
I T1 N0 M0 
IIA T2 N0 M0 
IIB T3 N0 M0 
IIIA T4 N0 M0 
IIIB Any T N1 M0 
IV Any T Any N M1 
 
 
Liver– Hepatocellular Carcinoma С220 
Stage Т N M 
I T1 N0 M0 
II T2 N0 M0 
IIIA T3a N0 M0 
IIIB T3b N0 M0 
IIIC T4 N1 M0 
IVA Any T N1 M0 
IVB Any T Any N M1 
 
 
Liver– Intrahepatic Bile Duct С221 
Stage Т N M 
I T1 N0 M0 
II T2 N0 M0 
III T3 N0 M0 
IVA T4 N0 M0 
Any T N1 M0 
IVB Any T Any N M1 
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Gallbladder С23 
Stage Т N M 
0 Tis N0 M0 
I T1 N0 M0 
II T2 N0 M0 
IIIA T3 N0 M0 
IIIB T1, T2, T3 N1 M0 
IVA T4 Any N M0 
IVB Any T Any N M1 
 
 
Extrahepatic Bile Ducts-Perihiliar С240 
Stage Т N M 
0 Tis N0 M0 
I T1 N0 M0 
II T2a, T2b N0 M0 
IIIA T3 N0 M0 
IIIB T1, T2, T3 N1 M0 
IVA T4 N0, N1 M0 
IVB Any T Any N M1 
 
 
Extrahepatic Bile Ducts-Distal С240 
Stage Т N M 
0 Tis N0 M0 
IA T1 N0 M0 
IB T2 N0 M0 
IIA T3 N0 M0 
IIB T1, T2, T3 N1 M0 
III T4 Any N M0 
IV Any T Any N M1 
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Ampulla of Vater С241 
Stage Т N M 
0 Tis N0 M0 
IA T1 N0 M0 
IB T2 N0 M0 
IIA T3 N0 M0 
IIB T1, T2, T3 N1 M0 
III T4 Any N M0 
IV Any T Any N M1 
 
 
Pancreas С25 
Stage Т N M 
0 Tis N0 M0 
IA T1 N0 M0 
IB T2 N0 M0 
IIA T3 N0 M0 
IIB T1, T2, T3 N1 M0 
III T4 Any N M0 
IV Any T Any N M1 
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Lung С34 
Stage Т N M 
Occult carcinoma TХ N0 M0 
0 Tis N0 M0 
IA T1a, T1b N0 M0 
IB T2a N0 M0 
IIA T2b N0 M0 
T1a, T1b N1 M0 
T2a N1 M0 
IIB T2b N1 M0 
T3 N0 M0 
IIIA T1a, T1b, T2a, T2b N2 M0 
T3 N1, N2 M0 
T4 N0, N1 M0 
IIIB Any T N3 M0 
T4 N2 M0 
IV Any T Any N M1 
 
 
Pleural Mesothelioma С384 
Stage Т N M 
IA T1a N0 M0 
IB T1b N0 M0 
II T2 N0 M0 
III T1, T2 N1 M0 
T1, T2 N2 M0 
T3 N0, N1, N2 M0 
IV T4 Any N M0 
Any T N3 M0 
Any T Any N M1 
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Bone С40, С41 
Stage Т N M Grade (G) 
IA T1 N0 M0 1, 2 
IB T2 N0 M0 1, 2 
IIA T1 N0 M0 3, 4 
IIB T2 N0 M0 3, 4 
III T3 N0 M0 Any G 
IVA Any T N0 M1a Any G 
IVB Any T N1 Any M Any G 
Any T Any N M1b Any G 
 
Note: Use N0 for NX. For T1 and T2, use low grade if no grade is stated. 
 
 
Soft Tissues С381-C383, С47, C480, С49 
Stage Т N M Grade (G) 
IA T1a N0 M0 1, 2 
T1b N0 M0 1, 2 
IB T2a N0 M0 1, 2 
T2b N0 M0 1, 2 
IIA T1a N0 M0 3, 4 
T1b N0 M0 3, 4 
IIB T2a N0 M0 3, 4 
III T2b N0 M0 3, 4 
Any T N1 M0 Any G 
IV Any T Any N M1 Any G 
 
Note: Use low grade for GX. Use N0 for NX. 
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Carcinoma of Skin of Eyelid С441 
Stage Т N M 
0 Tis N0 M0 
IA T1 N0 M0 
IB T2a N0 M0 
IC T2b N0 M0 
II T3a N0 M0 
IIIA T3b N0 M0 
IIIB Any T N1 M0 
IIIC T4 Any N M0 
IV Any T Any N M1 
 
 
Carcinoma of Skin (excluding eyelid, vulva, and penis) С440, C442-C449, С632 
Stage Т N M 
0 Tis N0 M0 
I T1 N0 M0 
II T2 N0 M0 
III T3 N0 M0 
T1, T2, T3 N1 M0 
IV T1, T2, T3 N2, N3 M0 
T4 Any N M0 
Any T Any N M1 
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Malignant Melanoma of Skin C44, C510, C609, C632 
Stage Т N M 
0 pTis N0 M0 
I pT1 N0 M0 
IA pT1a N0 M0 
IB pT1b N0 M0 
pT2a N0 M0 
IIA pT2b N0 M0 
pT3a N0 M0 
IIB pT3b N0 M0 
pT4a N0 M0 
IIC pT4b N0 M0 
III Any pT N1, N2, N3 M0 
IIIA pT1a-pT4a N1a, N2a M0 
IIIB pT1a-pT4a N1b, N2b, N2c M0 
pT1b-pT4b N1a, N2a, N2c M0 
IIIC pT1b-pT4b N1b, N2b M0 
Any pT N3 M0 
IV Any pT Any N M1 
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Malignant Melanoma of Uvea С693, C694 
Stage Т N M 
I T1a N0 M0 
IIA T1b-T1d, T2a N0 M0 
IIB T2b, T3a N0 M0 
IIIA T2c-T2d N0 M0 
T3b-T3c N0 M0 
T4a N0 M0 
IIIB T3d N0 M0 
T4b-T4c N0 M0 
IIIC T4d-T4e N0 M0 
IV Any T N1 M0 
Any T Any N M1 
 
 
Merkel Cell Carcinoma of Skin С440-C449, C632 
Stage Т N M 
0 Tis N0 M0 
I T1 N0 M0 
IA T1 pN0 M0 
IB T1 cN0 M0 
IIA T2, T3 pN0 M0 
IIB T2, T3 cN0 M0 
IIC T4 N0 M0 
IIIA Any T N1a M0 
IIIB Any T N1b, N2 M0 
IV Any T Any N M1 
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Breast Tumours С50 
Stage Т N M 
0 Tis N0 M0 
IA T1* N0 M0 
IB T0, T1* N1mi M0 
IIA T0, T1* N1 M0 
T2 N0 M0 
IIB T2 N1 M0 
T3 N0 M0 
IIIA T0, T1*, T2 N2 M0 
T3 N1, N2 M0 
IIIB T4 N0, N1, N2 M0 
IIIC Any T N3 M0 
IV Any T Any N M1 
*  T1 includes T1mi. 
 
 
Vulva С51 
Stage Т N M 
0 Tis N0 M0 
I T1 N0 M0 
IA T1а N0 M0 
IB T1b N0 M0 
II T2 N0 M0 
IIIA T1, T2 N1a, N1b M0 
IIIB T1, T2 N2a, N2b M0 
IIIC T1, T2 N2c M0 
IVA T1, T2 N3 M0 
T3 Any N M0 
IVB Any T Any N M1 
92   |   A proposal on cancer data quality checks: one common procedure for European cancer registries 
 
 
 
Vagina С52 
Stage Т N M 
0 Tis N0 M0 
I T1 N0 M0 
II T2 N0 M0 
III T3 N0 M0 
T1, T2, T3 N1 M0 
IVA T4 Any N M0 
IVB Any T Any N M1 
 
 
Cervix Uteri С53 
Stage Т N M 
0 Tis N0 M0 
I T1 N0 M0 
IA T1a N0 M0 
IA1 T1a1 N0 M0 
IA2 T1a2 N0 M0 
IB T1b N0 M0 
IB1 T1b1 N0 M0 
IB2 T1b2 N0 M0 
II T2 N0 M0 
IIA T2a N0 M0 
IIA1 T2a1 N0 M0 
IIA2 T2a2 N0 M0 
IIB T2b N0 M0 
III T3 N0 M0 
IIIA T3a N0 M0 
IIIB T1, T2, T3 N1 M0 
T3b Any N M0 
IVA T4 Any N M0 
IVB Any T Any N M1 
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Stage 
IA 
IB 
II 
IIIA 
IIIB 
IIIC 
IVA 
IVB 
Corpus Uteri С541, C55 
Т N M 
Uterini Sarcoma: 
Leiomyosarcoma (8890/3, endometrial stromal sarcoma (8930/3) and adenosarcoma (8933/3) 
C53, C540, C543 
Stage 
I 
IA 
IB 
IC* 
II 
IIA 
IIB 
IIIA 
IIIB 
IIIC 
IVA 
Т N M 
IVB 
T1a N0 M0 
T2 N0 M0 
T3b N0 M0 
T4 Any N M0 
T1 N0 M0 
T1b N0 M0 
T2 N0 M0 
T2b N0 M0 
T3b N0 M0 
T4 Any N M0 
T1b N0 M0 
T3a N0 M0 
T1, T2, T3 N1 M0 
Any T Any N M1 
T1a N0 M0 
T1c N0 M0 
T2a N0 M0 
T3a N0 M0 
T1, T2, T3 N1 M0 
Any T Any N M1 
 
Corpus Uteri С541, C55 
Stage Т N M 
IA T1a N0 M0 
IB T1b N0 M0 
II T2 N0 M0 
IIIA T3a N0 M0 
IIIB T3b N0 M0 
IIIC T1, T2, T3 N1 M0 
IVA T4 Any N M0 
IVB Any T Any N M1 
 
 
Uterine Sarcoma: 
Leiomyosarcoma (8890/3), endometrial stromal sarcoma (8930/3) and adenosarcoma (8933/3) 
C53, C540, 43 
Stage Т N M 
I T1 N0 M0 
IA T1a N0 M0 
IB T1b N0 M0 
IC* T1c N0 M0 
II T2 N0 M0 
IIA T2a N0 M0 
IIB T2b N0 M0 
IIIA T3a N0 M0 
IIIB T3b N0 M0 
IIIC T1, T2, T3 N1 M0 
IVA T4 Any N M0 
IVB Any T Any N M1 
 
*  Stage IC does not apply for leiomyosarcoma and endometrial stromal sarcoma. 
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Ovary С56 
Stage Т N M 
IA T1a N0 M0 
IB T1b N0 M0 
IC T1c N0 M0 
IIA T2a N0 M0 
IIB T2b N0 M0 
IIC T2c N0 M0 
IIIA T3a N0 M0 
IIIB T3b N0 M0 
IIIC T3c N0 M0 
Any T N1 M0 
IV Any T Any N M1 
 
 
Fallopian Tube С570 
Stage Т N M 
0 Tis N0 M0 
IA T1a N0 M0 
IB T1b N0 M0 
IC T1c N0 M0 
IIA T2а N0 M0 
IIB T2b N0 M0 
IIC T2c N0 M0 
IIIA T3a N0 M0 
IIIB T3b N0 M0 
IIIC T3c N0 M0 
Any T N1 M0 
IV Any T Any N M1 
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Gestational Trophoblastic Tumours С58 
Stage Т N – not applicable M Risk category 
I T1  M0 unknown 
IA T1  M0 low 
IB T1  M0 high 
II T2  M0 unknown 
IIA T2  M0 low 
IIB T2  M0 high 
III Any T  M1a unknown 
IIIA Any T  M1a low 
IIIB Any T  M1a high 
IV Any T  M1b unknown 
IVA Any T  M1b low 
IVB Any T  M1b high 
 
 
Penis С60 
Stage Т N M 
0 Tis N0 M0 
Tа N0 M0 
I T1a N0 M0 
II T1b N0 M0 
T2 N0, N1 M0 
T3 N0 M0 
IIIA T1, T2, T3 N1 M0 
IIIB T1, T2, T3 N2 M0 
IV T4 Any N M0 
Any T N3 M0 
Any T Any N M1 
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Prostate С61 
Stage Т N M 
I T1, T2a N0 M0 
II T2b, T2c N0 M0 
III T3 N0 M0 
IV T4 N0 M0 
Any T N1 M0 
Any T Any N M1 
 
 
Теstis С62 
Stage Т N M Serum tumour markers 
0 pTis N0 M0 S0, SX 
I pT1-T4 N0 M0 SX 
IA pT1 N0 M0 S0 
IB pT2-T4 N0 M0 S0 
IS Any pT/Tx N0 M0 S1-S3 
II Any pT/Tx N1-N3 M0 SX 
IIA Any pT/Tx N1 M0 S0 
Any pT/Tx N1 M0 S1 
IIB Any pT/Tx N2 M0 S0 
Any pT/Tx N2 M0 S1 
IIC Any pT/Tx N3 M0 S0 
Any pT/Tx N3 M0 S1 
III Any pT/Tx Any N M1a SX 
IIIA Any pT/Tx Any N M1a S0 
Any pT/Tx Any N M1a S1 
IIIB Any pT/Tx N1-N3 M0 S2 
Any pT/Tx Any N M1a S2 
IIIC Any pT/Tx N1-N3 M0 S3 
Any pT/Tx Any N M1a S3 
Any pT/Tx Any N M1b Any S 
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Kidney С64 
Stage Т N M 
I T1 N0 M0 
II T2 N0 M0 
III T3 Any N M0 
T1, T2, T3 N1 M0 
IV T4 Any N M0 
Any T N2 M0 
Any T Any N M1 
 
 
Renal Pelvis and Ureter С65, С66 
Stage Т N M 
0a Ta N0 M0 
0is Tis N0 M0 
I T1 N0 M0 
II T2 N0 M0 
III T3 N0 M0 
IV T4 N0 M0 
Any T N1, N2, N3 M0 
Any T Any N M1 
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Urinary Bladder С67 
Stage Т N M 
0a Ta N0 M0 
0is Tis N0 M0 
I T1 N0 M0 
II T2a, T2b N0 M0 
III T3a, T3b N0 M0 
T4a N0 M0 
IV T4b N0 M0 
Any T N1, N2, N3 M0 
Any T Any N M1 
 
 
Urethra С680 and C619 (transitional cell carcinomas) 
Stage Т N M 
0a Ta N0 M0 
0is Tis N0 M0 
Tispu N0 M0 
Tispd N0 M0 
I T1 N0 M0 
II T2 N0 M0 
III T1, T2 N1 M0 
T3 N0, N1 M0 
IV T4 N0, N1 M0 
Any T N2 M0 
Any T Any N M1 
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Adrenal Cortex Tumours С740 
Stage Т N M 
I T1 N0 M0 
II T2 N0 M0 
III T1, T2 N1 M0 
T3 N0 M0 
IV T3 N1 M0 
T4 Any N M0 
Any T Any N M1 
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